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Abstract	
	 In	the	study	of	reproductive	toxicology,	animal	models	play	an	important	role	in	
elucidating	the	mechanisms	by	which	a	toxicant	exerts	its	deleterious	effects,	as	well	as	serving	
as	a	translational	system	for	comparison	to	human	biology.	The	anatomy,	physiology,	and	
molecular	mechanisms	of	the	reproductive	system	of	these	models	should	first	be	well	
characterized	within	the	species	prior	to	making	inter-species	predictions	on	the	toxicant’s	
effects.	Here	we	conducted	a	systematic	analysis	of	the	available	literature	to	characterize	
within	the	rat	model	how	three	different,	popular	outbred	strains	(Wistar,	Sprague-Dawley,	and	
Long-Evans)	may	each	possess	distinct	levels	of	basal	peripheral	testosterone	(T),	estradiol	(E2),	
or	progesterone	(P4)	levels,	according	to	rat	sex	and	age.	We	found	that	estradiol	and	
testosterone,	but	not	progesterone,	were	different	depending	on	rat	strain,	which	could	possibly	
point	to	inherent	differences	in	the	hormonal	regulatory	systems	between	strains,	and	also	
potential	differences	between	strains	in	susceptibility	to	the	detrimental	effects	of	reproductive	
toxicants.	As	an	extension	of	this	analysis	of	the	factors	that	influence	sex	hormones,	we	also	
examined	the	effect	of	the	known	endocrine	disrupting	chemical,	bisphenol-A	(BPA),	at	
environmentally	relevant	ranges	on	the	sex	hormones,	follicle-stimulating	hormone	(FSH),	
luteinizing	hormone	(LH),	T,	E2,	and	P4	in	perinatally	exposed,	infantile	rats.	We	found	no	effect	
of	BPA	on	sex	hormone	levels	in	these	rats,	which	is	in	both	concordance	and	opposition	to	
other	studies	that	have	examined	this	developmental	time	point.	The	current	contradictory	
nature	of	the	literature	regarding	the	effect	of	environmentally	relevant	dosages	of	BPA	could	
benefit	from	an	examination	of	the	factors	other	than	toxicant	exposure	leading	to	the	different	
results.	
		 iii	
Acknowledgements	
	 To	my	Master’s	committee	for	their	guidance	and	time;	my	adviser,	Dr.	Sidonie	Lavergne	
for	her	passion	and	faith	in	me;	and	Dr.	David	Schaeffer	for	his	expert	advice	and	counsel.	To	the	
Juraska	Lab	and	Leslie	Wise	for	the	hard	work	and	samples	they	provided	for	the	BPA	study.	To	
the	 Comparative	 Biosciences	 program	 and	 fellow	 graduate	 students	 and	 other	 departmental	
professors	 at	 the	University	 of	 Illinois	 for	 giving	me	 this	 opportunity	 to	 advance	my	 scientific	
skills	and	learn	from	you	all.	To	my	family	and	friends,	I	thank	you	all	for	your	unending	support.	
	 	
		 iv	
Table	of	Contents	
Thesis	Introduction	..................................................................................................................	1	
The	Study	of	Reproductive	Toxicology	.........................................................................................	1	
The	Role	of	Animal	Models	in	Reproductive	Toxicology	..............................................................	2	
Sex	Hormones	..............................................................................................................................	4	
Steroidal	sex	hormones	...........................................................................................................	4	
Peptide	sex	hormones	.............................................................................................................	6	
The	hypothalamic-pituitary-gonadal	axis	.....................................................................................	7	
Sex	hormone	variability	factors	...................................................................................................	7	
Reference	Information	for	Sex	Hormones	...................................................................................	8	
Thesis	Goals	.................................................................................................................................	9	
References	.................................................................................................................................	11	
Chapter	1:	A	Systematic	Analysis	of	the	Literature	to	Evaluate	the	Effect	of	Strain	on	Peripheral	
Sex	Hormone	Levels	in	Rats	....................................................................................................	18	
Introduction	...............................................................................................................................	18	
Methods	.....................................................................................................................................	20	
Article	search	.........................................................................................................................	20	
Data	collected	from	each	article	............................................................................................	21	
Determination	of	statistical	distributions	..............................................................................	21	
Simulated	dataset	generation	................................................................................................	22	
Data	analysis	..........................................................................................................................	22	
Results	........................................................................................................................................	23	
Kit	and	Tissue	Effect	...............................................................................................................	23	
Sex	Effect	................................................................................................................................	24	
Age	Effect	...............................................................................................................................	26	
Strain	Effect	............................................................................................................................	30	
Discussion	..................................................................................................................................	33	
Conclusions	................................................................................................................................	36	
Tables	.........................................................................................................................................	38	
References	.................................................................................................................................	48	
Chapter	2:		Effect	of	Perinatal	Exposure	to	Bisphenol-A	on	Sex	Hormone	Levels	in	Young	Rats50	
Introduction	...............................................................................................................................	50	
Methods	.....................................................................................................................................	52	
Housing	and	Diet	....................................................................................................................	52	
BPA	exposure	.........................................................................................................................	52	
Sample	collection	and	processing	..........................................................................................	54	
FSH/LH	measurement	............................................................................................................	54	
Steroid	extraction	..................................................................................................................	54	
Steroid	sex	hormone	ELISA	....................................................................................................	55	
Statistical	analysis	..................................................................................................................	55	
Results	........................................................................................................................................	57	
Sex	differences	.......................................................................................................................	57	
Treatment	effect	....................................................................................................................	57	
		 v	
Discussion	..................................................................................................................................	58	
Sex	differences	.......................................................................................................................	58	
Treatment	effect	....................................................................................................................	59	
Study	Limitations	...................................................................................................................	61	
Conclusions	................................................................................................................................	61	
Tables	and	Figures	.....................................................................................................................	63	
References	.................................................................................................................................	68	
Overall	Thesis	Conclusion	.......................................................................................................	72	
Appendix	...............................................................................................................................	74	
	
		 1	
Thesis	Introduction	
The	Study	of	Reproductive	Toxicology	
The	 academic	 discipline	 of	 reproductive	 toxicology	 has	 been	 defined	 as	 the	 study	 of	
chemicals	and	agents	on	the	reproductive	system	and	the	identification	of	adverse	effects	that	
interfere	with	the	process	of	successful	and	healthy	reproduction	(Hood	2011).	The	field	studies	
the	 disruptive	 effects	 of	 exogenous	 substances	 on	 the	 reproductive	 physiology	 of	 both	 sexes,	
and	 is	 intimately	 intertwined	 with	 the	 fields	 of	 teratology,	 developmental	 biology,	 and	
endocrinology.	 Such	 chemicals	 that	 are	 specifically	 identified	 as	 harmful	 to	 reproductive	
functioning	 are	 then	 subjected	 to	 experimentation	 to	 identify	 the	mechanisms	 by	which	 they	
might	 exert	 their	 deleterious	 effects.	 These	 effects	 typically	will	 be	 noticeable	 at	 the	 gonadal	
level,	 and	 consequently,	 also	 at	 the	 hypothalamic	 and	 pituitary	 levels	 due	 to	 the	 functional	
association	of	the	three	tissues	in	the	hypothalamic-pituitary-gonadal	(HPG)	axis	(Peretz,	et	al.,	
2011).	In	addition	to	the	gonad	and	the	major	axis	that	controls	them,	reproductive	toxicologists	
can	also	focus	on	the	accessory	sex	organs:	the	oviducts,	uterus,	vagina,	and	mammary	glands	in	
the	female,	and	the	epididymis,	seminal	vesicles,	and	prostate	 in	the	male.	Harmful	effects	on	
fertility	 are	 also	 evaluated	 beginning	 with	 sexual	 behavior,	 conception,	 and	 continuing	
throughout	pregnancy	and	eventually	parturition	(Peretz,	et	al.,	2011).	The	more	recent	interest	
in	 reproductive	 toxicology	 even	 extends	 into	 transgenerational	 effects	 in	 offspring	 (Skinner	
2007;	Skinner,	et	al.,	2010).	
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The	Role	of	Animal	Models	in	Reproductive	Toxicology	
Although	 new	 in	 vitro	 molecular	 and	 cellular	methods	 have	 continued	 to	 emerge	 and	
advance	in	recent	years,	the	reality	of	in	vivo	animal	testing	will	likely	persist	due	to	the	need	for	
whole-system	 assessment	 of	 a	 toxicant’s	 effects	 (Hood,	 2006).	 Laboratory	 bred	 animals	 have	
served	 this	 purpose	 to	 extrapolate	 findings	 and	 comparatively	 explain	 human	 processes.	 An	
animal	model	is	chosen	based	on	the	specific	requirements	of	a	research	question	and/or	study	
design.	 The	general	 consensus	 in	 reproductive	 toxicology	 is	 that	 the	animal	model	 chosen	 for	
primary	screening	of	a	chemical	should	(1)	have	a	maternal-placental-fetal	relationship	similar	to	
humans,	and	thus	mammals	are	preferable,	(2)	have	a	short	gestation	period,	with	a	large	litter	
size,	and	easy	mode	of	breeding,	and	(3)	be	economically	easy	to	house	and	technically	easy	to	
handle	and	collect	samples	from	(Kacew	2001;	Schardein,	et	al.,	1985).	
Thus,	 animal	 models	 in	 reproductive	 toxicology	 have	 traditionally	 involved	 rodents	—
usually	mice	or	rats—,	but	also	rabbits,	dogs,	and	some	non-human	primates	(Schardein,	et	al.,	
1985);	large	animals	with	prolonged	gestation	are	only	usually	used	in	cases	where	the	issue	of	
teratogenicity	needs	 to	be	examined	 in	more	detail.	 Invertebrates,	 fish,	amphibians,	and	birds	
are	 usually	 utilized	 mainly	 for	 the	 recognition	 of	 ecotoxicity,	 rather	 than	 for	 comparison	 to	
human	 physiology	 as	 they	 have	 demonstrated	 a	 greater	 number	 of	 differences	 in	 their	
responses	to	toxicant	exposure	than	when	comparing	humans	to	other	mammals	(Touart	2006).	
Nonetheless,	the	zebrafish,	Xenopus	laevis,	and	the	chicken	have	all	been	invaluable	models	that	
have	facilitated	the	study	of	early	embryonic	development	(Oelgeschläger	2014).	
However,	no	one	species	shares	entirely	similar	traits	to	humans,	and	thus	is	best	suited	
for	 comparison	as	noted	by	Amann	 (1982).	 Since	 the	degree	of	 control	 is	 one	of	 the	defining	
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aspects	of	any	good	study,	an	animal	model	should	be	chosen	for	specific	reasons	relating	to	the	
objective	of	the	experimental	hypothesis.	As	an	example,	rats	are	usually	preferred	to	mice	and	
hamsters	for	their	augmented	intelligence	and	organ	size,	and	as	a	popular	animal	for	toxicology	
studies	historically,	 their	 reproductive	 characterization	 is	well	 documented	 (Gray,	 et	 al.,	 2010;	
Hedrich,	2000;	Kacew,	2001;	Weber,	et	al.,	2010).	The	rat	model	has	been	used	for	decades	in	
reproductive	toxicology	and	other	biological	sciences.	Thus,	a	plethora	of	phenotypic	reference	
information	is	available	through	databases	such	as	the	Rat	Genome	Database	(RGD),	which	has	
consolidated	a	variety	of	physiologic	measurements	that	can	be	searched	based	on	the	type	of	
clinical	measurement,	experimental	condition,	measurement	method,	or	strain	(Laulederkind,	et	
al.,	 2013).	 However,	 the	 rat	 is	 not	 an	 ideal	 candidate	 for	 longitudinal	 study	 of	 semen	 or	
spermatozoa	(Amann,	1982).	Mice	and	rats	are	known	to	be	different	 from	humans	 in	several	
aspects	 of	 the	 process	 of	 implantation:	 such	 as	 the	 ability	 to	 delay	 implantation	 after	
fertilization,	and	the	rapid	speed	at	which	the	process	occurs,	making	it	a	difficult	model	for	the	
study	of	early	embryonic	events	(Lee	&	DeMayo,	2004).		Additionally,	measuring	fertility	by	the	
ability	to	produce	offspring	is	an	endpoint	that	is	not	nearly	as	sensitive	in	rodents	as	in	humans,	
since	rodents	normally	have	large	litter	sizes	and	are	robustly	fertile	compared	to	humans	(Seed,	
et	al.,	1996).	Observing	the	early	mechanisms	of	 implantation	may	be	better	suited	to	animals	
with	 a	 prolonged	 apposition	 and	 attachment	 phase,	 a	 characteristic	 of	 epitheliochorial	
placentaed	mammals	like	cows,	pigs,	and	sheep.	However,	rodents	present	numerous	practical	
advantages	 as	 animal	models	 in	 general	 (e.g.,	 similar	metabolic	 pathways,	 similar	 anatomical	
and	 physiological	 characteristics,	 small	 size,	 short	 life	 span)	 and	 in	 reproductive	 toxicology	
specifically:	 e.g.,	 short	 gestation	 time	 and	 large	 litter	 size	 (Kacew,	 2001).	 In	 summary,	 it	 is	
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important	 to	 utilize	 in-depth	 knowledge	 of	 the	 physiology	 of	 each	 species,	 and	 the	 known	
species	 homologies	 or	 divergences,	 in	 any	 discussion	 about	 the	 absence	 or	 presence	 of	
toxicological	 effects	 in	 studies	 using	 animal	models.	 It	 is	 also	 important	 to	 understand	 these	
intra-	and	interspecies	characteristics	when	comparing	studies.	
	
Sex	Hormones	
Steroidal	sex	hormones	
The	 sex	 hormones	 consist	 of	 the	 steroidal	 gonadal	 hormones,	 as	 well	 as	 several	 non-
steroidal	peptide	hormones	derived	from	the	anterior	pituitary.	The	gonadal	steroid	hormones	
are	usually	 general	 classified	as	androgens,	estrogens,	 and	progestrogens.	Androgens	 (derived	
from	 the	 Greek	 root	 “andro”	 that	means	 “male”)	 are	 typically	 associated	with	male	 features	
because	 of	 their	 key	 role	 in	 regulating	 the	 functions	 of	 the	 primary	 sex	 organs	 and	 the	
development	of	secondary	sex	characteristics	specific	to	males.	The	most	prominently	discussed	
androgen,	testosterone	(T),	is	known	to	promote	the	development	of	the	testis,	prostate,	sperm,	
body	 hair,	 and	 anabolic	 accumulation	 of	 muscle	 and	 bone	 mass,	 and	 was	 found	 to	 be	
approximately	ten	times	higher	in	adult	men	than	women	(Boulpaep,	et	al.,	2009;	Mooradian,	et	
al.,	 1987;	 Taieb,	 et	 al.,	 2003).	 Conversely,	 estrogens	 are	 associated	 with	 female	 sexual	
characteristics.	 The	major	 estrogen,	 17β-estradiol	 (estradiol	 or	 E2),	 is	 essential	 to	maintaining	
the	 tissues	 and	 secretions	 of	 the	 female	 reproductive	 system,	 and	 especially	 the	 lining	of	 the	
uterus	 as	 part	 of	 the	 estrous	 or	 menstrual	 cycle	 (Boulpaep,	 et	 al.,	 2009).	 17β-estradiol	 also	
promotes	 the	 development	 of	 female	 secondary	 sex	 characteristics	 by	 affecting	 bone	
development	during	puberty	and	site-specific	fat	deposition	leading	to	the	formation	of	breasts	
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(Belun	2014;	Boulpaep,	et	al.,	2009).	Despite	the	reputation	of	estradiol	as	a	“female	hormone”,	
it	 also	 plays	 an	 important	 role	 in	 males,	 such	 as	 in	 the	 early	 events	 of	 neuronal	 sexual	
differentiation	during	fetal	and	neonatal	development	by	masculinizing	specific	nuclei	within	the	
hypothalamus	 (McCarthy,	 2008).	 Progesterone,	 the	 major	 progestrogen,	 is	 secreted	 in	 high	
amounts	 by	 the	 female	 corpus	 luteum,	 and	 induces	 cell	 differentiation	 and	 secretions	 of	 the	
uterine	endometrium	during	the	estrous	cycle.	It	is	also	critical	for	implantation	of	the	fertilized	
embryo	and	the	maintenance	of	pregnancy	(Kim,	et	al.,	2013).	The	role	of	progesterone	in	the	
male	is	less	understood,	though	it	has	been	suggested	that	it	plays	a	role	during	development	on	
the	sexual	dimorphic	regions	of	the	brain	(Wagner,	2006).	
After	being	studied	for	decades,	the	cell	signaling	associated	with	steroidal	sex	hormones	
is	relatively	well	defined	(McKenna,	2015).	Testosterone	primarily	binds	to	the	nuclear	receptor	
androgen	receptor	(AR).	The	androgen	receptor	is	expressed	by	a	wide	variety	of	tissues,	but	is	
most	present	and	influential	in	reproduction-related	areas	in	the	brain	(e.g.,	the	medial	preoptic	
and	ventromedial	nuclei),	prostate,	seminal	vesicles,	testes,	ovaries,	and	uterus	(Dart	and	Alwyn,	
2013,	De	Winter,	et	al.,	1991;	Simerly,	et	al.,	1990).		Estradiol	binds	to	nuclear-located	estrogen	
receptors	 alpha	 and	 beta	 (ERα	 and	 ERβ,	 also	 known	 as	 ESR1	 and	 ESR2).	 These	 two	 types	 of	
classical	estrogen	receptor	are	widely	expressed	but	in	different	ratios	depending	on	the	tissue	
(Couse,	et	al.,	1997;	Kuiper,	et	al.,	1997;	Deroo	&	Korach,	2006).	The	progesterone	receptor	(PR)	
is	also	a	member	of	 the	nuclear	steroid-receptor	superfamily.	Progesterone	receptors	are	also	
ubiquitously	 expressed	 in	 a	 variety	of	 non-reproductive	 and	 reproductive	 tissue,	 including	 the	
uterus,	brain,	ovary,	and	testes	(Graham	&	Clarke,	1997;	Scarpin,	et	al.,	2009).		
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Peptide	sex	hormones	
The	gonadotropins,	luteinizing	hormone	(LH)	and	follicle-stimulating	hormone	(FSH),	are	
glycoproteins	 that	 are	 released	 from	 the	 gonadotroph	 neurons	 in	 the	 anterior	 pituitary	 in	
response	to	gonadotropin-releasing	hormone	(GnRH)	released	from	the	hypothalamus.	Both	LH	
and	 FSH	 are	 in	 the	 same	 family	 of	 glycoproteins	 as	 thyroid-stimulating	 hormone	 (TSH),	 all	 of	
which	 share	 the	 same	 alpha	 domain,	 while	 the	 beta	 domain	 defines	 their	 receptor-binding	
specificity	(Boulpaep,	et	al.,	2009).		
The	primary	action	of	LH	in	both	sexes,	is	to	stimulate	the	production	of	cholesterol	side	
chain	 cleaving	 enzyme,	 the	 first	 enzyme	 of	 the	 steroidogenic	 pathway	 in	which	 cholesterol	 is	
converted	into	the	various	steroid	hormones.	 	LH	regulates	androstenedione	production	in	the	
theca	cells	of	the	ovary,	the	precursor	to	both	testosterone	and	estradiol	(Belun	&	Adashi	2011).	
FSH	exerts	its	indirect	influence	on	steroidogenesis	by	promoting	female	ovarian	follicle	growth	
and	recruitment,	as	well	as	direct	influence	within	the	pathway	by	stimulating	aromatase	activity	
within	the	granulosa	cells	(Erickson	and	Hsueh	1978).	
In	females,	LH	binds	to	its	corresponding	receptor	integrated	within	the	cell	membranes	
of	the	steroid-secreting	ovarian	follicular	cells:	both	granulosa	and	theca	cells,	as	well	as	 luteal	
cells	during	 the	estrous	or	menstrual	 cycle	 (Ascoli	&	Fanelli	2002,	Boulpaep,	et	al.,	2009).	The	
FSH	 receptor	 is	 primarily	 expressed	 within	 the	 membranes	 of	 granulosa	 cells	 (Simoni,	 et	 al.,	
1997,	 Boulpaep,	 et	 al.,	 2009).	 It	 	 regulates	 estradiol	 production	 and	 the	 growth	 of	 ovarian	
follicles.	Both	FSH	and	LH	together	are	required	to	produce	estradiol	during	steroidogenesis	 in	
the	female	because	no	one	cell	type,	theca	or	granulosa	cell,	is	able	to	produce	progesterone	on	
its	 own	 (Boulpaep,	 et	 al.,	 2009;	 Magoffin,	 2005).	 In	 males,	 LH	 receptors	 are	 located	 on	 the	
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steroid-secreting	 testicular	 Leydig	 cells,	whereas	 the	 role	of	 FSH	 is	mainly	on	 the	 Sertoli	 cells,	
which	regulate	spermatogenesis	(Asatiani,	et	al.,	2002,	Boulpaep,	et	al.,	2009).		
	
The	hypothalamic-pituitary-gonadal	axis	
The	regulatory	relationship	between	steroid	sex	hormones	and	glycoprotein	
gonadotropins	(FSH	and	LH)	is	the	basis	for	the	hypothalamic-pituitary-gonadal	axis.	The	
production	of	steroid	hormones	by	the	gonads	is	stimulated	by	glycoprotein	gonadotropins.	The	
steroid	hormones	in	turn	feedback	to	both	the	hypothalamus	and	pituitary	gland	to	down-
regulate	the	production	of	the	gonadotropins.	This	hormonal	regulation	loop	develops	in	a	step-
wise	fashion	from	birth	until	puberty	(Boulpaep,	et	al.,	2009).			
	
Sex	hormone	variability	factors	
In	 addition	 to	 intrinsic	 physiological	 mechanisms	 of	 sex	 hormone	 regulation,	 external	
factors	 are	 known	 to	 affect	 hormone	 levels.	 Some	 factors	 are	 endogenous:	 e.g.,	 sleep-wake	
diurnal	patterns	(Winters	1991;	Tenover,	et	al.,	1988;	Reinberg	&	Lagoguy	1978;	Reinberg,	et	al.,	
1975;	Plymate,	et	al.,	1989;	Nicolau,	et	al.,	1984a,b;	Montanini,	et	al.,	1988;	Lévi,	et	al.,	1988;	
Faiman	&	Winter	1971;	Diver,	et	al.,	2003;	de	la	Torre,	et	al.,	1981;	Cooke,	et	al.,	1993;	Bremner,	
et	 al.,	 1983),	 pregnancy	 (Kacew	 2001),	 psychogenic	 or	 physical	 stress	 (Belun	 &	 Adashi	 2011,	
Rivier	 &	 Rivest	 1991),	 or	 amount	 of	 body	 fat	 (Tchernof	 &	 Despres	 1999).	 Other	 factors	 are	
exogenous:	 light-dark	exposure	 (Critser,	et	al.,	1987,	Fantie,	et	al.,	1984),	endocrine	disrupting	
chemicals	(Diamanti-Kandarakis,	et	al.,	2009;	Gore,	et	al.,	2015;	Gupta,	et	al.,	2010;	Peretz,	et	al.,	
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2011;	 Sharara,	 et	 al.,	 1998),	 hormone-supplementation	 regimens,	 and	 some	 therapeutic	
pharmacological	agents	(Geisler,	et	al.,	2002;	Mattson	&	Cramer	1985;	Merkatz,	et	al.,	1993).	
	 	
Reference	Information	for	Sex	Hormones	
Due	 to	 the	 widespread	 influence	 that	 sex	 hormones	 have	 on	 physiology,	 and	 their	
foremost	role	in	regulation	of	reproductive	function	and	development,	their	levels	as	measured	
in	 circulation	 constitute	 an	 important	 endpoint	 in	 many	 reproductive	 toxicology	 studies	
(Goldman,	et	al.,	2007,	Melnick,	et	al.,	2002).	However,	 the	 inclusion	of	 sex	hormone	 levels	 is	
sometimes	listed	as	an	optional	endpoint	in	experimental	guidelines,	likely	due	to	concerns	over	
assay	sensitivity	and	accuracy,	and	inherent	physiological	difficulties	in	obtaining	reproducible	or	
representative	 measurements	 (Holmes,	 et	 al.,	 1998;	 McMaster,	 et	 al.,	 2001;	 Rosner,	 et	 al.,	
2007).		
Ideally,	any	blood	chemistry	measurement	should	be	compared	to	a	measurement	from	
a	control	sample	taken	from	within	the	same	individual.	However,	this	is	not	always	feasible	due	
to	 the	 constraint	 of	 time	 and	 small	 blood	 volume	 of	 common	 laboratory	 animals.	 Therefore,	
other	control	methods	have	been	accepted	as	reasonable,	such	as	a	separate	untreated	group,	
vehicle-treated	 group,	 or	 sham-operated	 group	 in	 studies	 involving	 a	 surgery,	 with	 these	
controls	 undergoing	 the	 full	 extent	 of	 the	 experimental	 conditions	 at	 the	 same	 time	 as	 the	
chemically-treated	group	(Johnson	&	Besselsen	2002).	 In	addition	to	control	groups,	 reference	
intervals	for	blood	chemistry	are	also	useful.	Such	ranges	are	often	used	in	the	clinical	setting	for	
pathological	determination	and	can	be	used	to	estimate	the	test	sensitivity	that	will	be	required	
to	measure	 sex	 hormone	 levels	 in	 new	 samples	 from	 a	 specific	 study.	 Reference	 intervals,	 in	
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either	research	or	clinics,	should	also	be	established	internally	within	the	laboratory	that	is	to	be	
performing	 the	 procedure	 whenever	 possible	 (Jones	 &	 Barker	 2008,	 Jung	 &	 Adeli	 2009).	
Especially	 in	cases	of	sex	hormones,	which	are	highly	variable	as	a	result	of	numerous	factors,	
the	 establishment	 of	 a	 normal	 range	 of	 values	 based	 on	 healthy	 individuals	 can	 assist	 in	
determining	 whether	 any	 particular	 laboratory	 finding	 is	 of	 interpretable	 value	 by	 first	
determining	if	the	measured	hormone	level	will	have	the	accuracy,	precision,	and	concordance	
with	respect	to	these	factors.		
Gender-,	 age-,	 and	 cycle-	 specific	 reference	 intervals	 of	 sex	 hormone	 levels	 have	been	
described	 extensively	 for	 humans,	 although	 generally	 in	 healthy	 populations	 (Ukkola,	 et	 al.,	
2001;	Eskelinen,	et	al.,	2007;	Schüring,	et	al.,	2016;	Elmlinger,	et	al.,	2002;		Bhasin,	et	al.,	2011;	
Kishnir,	 et	 al.,	 2010;	 Soldin,	 et	 al.,	 2005,	Milewicz,	 et	 al.,	 2013).	 There	 are	more	 limited	 data	
available	for	mice	(McNamara,	et	al.,	2010).	Although	the	Rat	Genome	Database	is	an	excellent	
tool	for	the	organization	of	published	studies	reporting	other	blood	chemistry	data,	the	amount	
of	 information	 on	 sex	 hormone	 levels	 in	 the	 database	 shows	 high	 variability	 in	 terms	 of	
concentration	 values	 from	 less	 than	 ten	 small	 individual	 studies	 that	 used	 different	
methodology,	and	collectively	included	a	small	number	of	strains	and	age	points	(Laulederkind,	
et	al.,	2013).		
	
Thesis	Goals	
The	 aspects	 of	 this	 thesis	 are	 two-fold.	 First,	 this	 thesis	 project	 was	 designed	 to	
investigate	the	conceptual	features	of	the	study	of	reproductive	toxicology,	specifically	the	role	
of	 sex	 hormones	 as	 an	 experimental	 endpoint,	 and	 the	 study	 design	 characteristics	 on	which	
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their	measurement	values	are	so	heavily	dependent.	Based	on	all	of	the	above	considerations,	I	
first	 evaluated	 one	 possible	 determinant	 of	 sex	 hormone	 levels—strain—in	 a	 popular	 animal	
model,	 the	rat,	by	conducting	an	analysis	of	 the	available	 literature	to	evaluate	whether	there	
was	 an	 observable	 difference	 in	 steroid	 sex	 hormone	 measurements	 between	 strains	 of	 rat.	
Secondly,	 I	performed	a	 simple	 toxicological	assessment	of	 the	endocrine	disrupting	chemical,	
bisphenol-A	 (BPA)	on	 the	hormone	 levels	of	developing	 rats.	Overall,	 this	 thesis	demonstrates	
the	importance	of	commonly	overlooked	conceptual	elements	that	should	be	considered	when	
designing	a	reproductive	toxicology	study.	
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Chapter	1:	A	Systematic	Analysis	of	the	Literature	to	Evaluate	the	Effect	of	Strain	on	Peripheral	
Sex	Hormone	Levels	in	Rats	
	
Introduction	
The	laboratory	rat	has	served	an	important	historical	role	in	biomedical	and	psychological	
research	and	continues	as	a	widely	used	animal	model	of	human	physiology.	The	 similarity	of	
many	 anatomical	 and	 physiological	 traits	 to	 humans,	 small	 size,	 short	 gestation	 period,	
intelligence,	manageable	temperament,	and	economic	feasibility,	make	the	rat	a	choice	research	
model	 in	 a	 wide	 variety	 of	 disciplines.	 The	 amount	 of	 information	 on	 the	 characteristics	 of	
various	strains	and	stocks	 is	also	heavily	documented	and	available	 in	numerous	databases	for	
use	by	researchers.		
The	most	 commonly	 used	 rats	 in	 research,	 including	 generically	 named	 stocks,	Wistar,	
Sprague-Dawley,	Long-Evans,	Holtzmann,	Albany,	among	others,	are	all	derived	from	an	original	
randomly	bred	 (outbred)	 stock	of	 the	Norway	 rat	 (Rattus	norvegicus)	 (Hedrich	2000),	 and	are	
named	for	 their	historical	origin	more	than	 for	similar	genotypic	or	phenotypic	characteristics.	
These	 commercially	 available	 stocks	may	 be	 subdivided	 into	 colony	 designations	 within	 their	
breeding	facilities,	although	there	is	high	likelihood	of	genetic	variability	when	comparing	colony	
to	 colony	 due	 to	 less	 stringent	 breeding	 practices	 than	 inbred	 lines	 (Kacew	 &	 Festing	 1999).	
Although	 typically	 more	 expensive,	 inbred	 lines	 are	 desirable	 for	 their	 controlled,	 well	
documented,	 and	 virtually	 identical	 genotype	 resulting	 from	 a	 sequence	 of	 at	 least	 20	
generations	of	inbreeding,	and	are	typically	referred	to	as	distinct	strains,	rather	than	stocks	or	
colonies,	with	their	own	codes	denoting	the	outbred	line	from	which	they	originated.	
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When	 designing	 an	 animal	 experiment,	 there	 are	 numerous	 factors	 that	 must	 be	
carefully	 considered	about	 the	 research	model	 to	adequately	 control	 the	environment	 for	 the	
purpose	of	transparent	explanation	of	 findings	and	facilitate	reproducibility;	 these	 include	sex,	
age,	 physiological	 status	 (pregnant	 or	 diseased),	 nutrition,	 cohabitation,	 genetic	 history,	 and	
other	 factors.	 It	 is	 also	 important	 to	 consider	 the	 applicability	 of	 the	 research,	 and	 so	 the	
majority	of	toxicologists	have	historically	used,	and	continue	to	use,	genetically	heterogeneous	
outbred	 stocks	 of	 rats	 on	 the	 grounds	 that	 the	 it	 is	 most	 relevant	 to	 humans	 and	 their	
heterogeneous	 genetic	make-up.	 However,	 this	 strategy	 decreases	 the	 degree	 of	 control	 that	
the	 researcher	 has	 in	 the	 laboratory	 setting,	 increases	 variability,	 and	 can	 reduce	 statistical	
power,	 as	 the	exact	genetic	 lineage	of	 the	animal	 is	ultimately	unknown,	and	any	 conclusions	
alluding	 to	 genetic	 variability	 are	unfounded	 simply	due	 to	 lack	of	 specific	 characterization	or	
description	(Festing	2010).		
Although	 outbred	 stocks	 are	 known	 to	 be	 variable	 in	 genotype,	 attempts	 have	 been	
made	to	characterize	the	phenotypic	variability	of	both	outbred	and	inbred	rat	stocks	and	strains	
in	comparison	to	others,	mainly	to	raise	awareness	that	one	strain	or	stock	can	potentially	differ	
from	another	in	respect	to	its	response	to	any	particular	chemical	or	toxicant	(Kacew	&	Festing	
1999).	 Similarly	here,	we	attempted	 to	 characterize	 the	 sex	 steroid	hormone	profiles	of	 three	
popularly-used	 outbred	 stocks	 with	 respect	 to	 other	 major	 covariates	 such	 as	 age	 and	 sex.	
Information	 about	 the	 patterns	 in	 their	 sex	 hormones	 may	 facilitate	 the	 interpretation	 of	
historical	 studies	 that	have	used	outbred	 lines.	 In	 this	 study,	we	gathered	 reported	circulating	
peripheral	concentrations	of	three	steroid	sex	hormones—17-beta-estradiol	(E2),	progesterone	
(P4),	 and	 testosterone	 (T)—across	 the	 available	 literature	 that	 have	 utilized	 three	 common	
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outbred	 stocks	 (referred	 to	 hereon	 as	 strains	 for	 brevity),	 Sprague-Dawley,	Wistar,	 and	 Long-
Evans.	 We	 hypothesized	 that	 there	 will	 be	 recognizable	 strain	 variations	 in	 hormone	
concentrations,	with	sex-specific	hormone	patterns	depending	on	age. 
 
Methods	
Article	search	
Pubmed	 queries	 started	 from	 the	 earliest	 date	 available	 date	 (1956)	 until	 February	 of	
2015.	Google	Scholar	searches	of	the	same	queries	were	investigated	up	to	the	first	500	results	
when	 sorted	 by	 Google’s	 algorithmic	 determination	 of	 relevance	 due	 to	 the	 high	 volume	 of	
results.	 The	 two	 databases	were	 searched	 based	 on	 combinations	 of	 the	 following	 keywords:	
estrogen,	 progesterone,	 testosterone,	 rat,	 plasma,	 serum,	 Sprague	 Dawley,	 Long	 Evans,	 and	
Wistar.	
Then,	 articles	 were	 filtered	 using	 the	 specific	 inclusion	 criteria:	 (1)	 physiologically	 and	
anatomically	normal;	(2)	untreated	(naïve)	baseline	control	animals;	(3)	vehicle	control	animals	if	
the	vehicle	has	been	demonstrated	to	have	minimal	effect	on	the	physiological	processes	of	any	
organ	 system;	 (4)	 vehicle	 control	 animals	 if	 the	 vehicle	 volume	did	not	 exceed	 recommended	
volumes	for	rats	(0.5	ml	per	100	kg	bw)	(Turner,	et	al.,	2011)	or	over	0.5%	ethanol	(Rachdaoui	
and	 Sakar	 2013).	We	 also	 excluded	 studies	 that:	 (1)	 used	 substances	 known	 to	 alter	 baseline	
hormone	levels	or	general	physiology,	e.g.,	exogenous	sex	steroid	hormones,	soybean	oil	(rich	in	
phytoestrogens);	abnormal	diet	conditions,	e.g.,	high	caloric	diets,	starvation,	high	fat;	high-dose	
radiation;	 carcinogenic	 substances;	 (2)	 hormone	 concentrations	 from	 animals	 post-surgery	
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(sham	or	 experimental);	 (3)	 animals	 subjected	 to	 invasive	 procedures	 such	 as	 implantation	or	
cannulation;	(4)	diseased;	and	(5)	pregnant	or	pseudopregnant	rats.		
	
Data	collected	from	each	article	
We	 recorded	 bibliographic	 information:	 article	 title,	 authors,	 journal,	 and	 publication	
date.	We	 recorded	 summary	 statistics,	 e.g.,	means,	medians,	 standard	 error	 (SE)	 or	 deviation	
(SD),	95%	confidence	interval,	minimum	and	maximum	levels.	Methodological	details	collected	
included:	 number	 of	 animals	 used,	 tissue	 type	 (plasma	 or	 serum),	 and	 analytical	 technique	
(radioimmunoassay,	ELISA,	HPLC,	etc.).	We	recorded	any	demographic	data	about	the	rats,	e.g.,	
sex,	age	(postnatal	day	and/or	age	group	category),	breed,	weight,	estrous	cycle	stage,	time	of	
day,	and	diet	(e.g.,	soy-based	or	xenoestrogen-free).		
	
Determination	of	statistical	distributions	
Prior	 to	 analysis,	 the	 distributions	 of	 estrogen,	 progesterone,	 and	 testosterone	
concentrations	 were	 determined	 using	 the	 published	 number	 of	 animals	 per	 group	 and	
summary	statistics.	The	data	were	determined	to	have	lognormal	distributions	based	on	one	or	
more	of	the	following	criteria:	(1)	review	publications	that	reported	that	biological	data	usually	
have	 a	 log-normal	 distribution;	 (2)	 the	 publication	 from	 which	 hormone	 data	 was	 extracted	
stated	that	the	distribution(s)	was	log-normal;	(3)	the	mean	and	median	were	not	equal;	(4)	the	
mean	was	 less	 than	 twice	 the	SD,	 the	CI	 included	 zero,	or	 the	minimum	was	negative;	 (5)	we	
compared	 the	 fit	 of	 the	data	 for	 individual	 animals	 (when	 reported)	 to	normal	 and	 lognormal	
distributions.	The	arithmetic	mean	and	SD	or	SE	of	hormone	groups	were	used	in	the	equation	
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described	 below	 to	 determine	 the	 parameters	 (estimated	 population	 mean	 and	 standard	
deviation,	𝜇	and	𝜎,	 respectively)	 of	 the	 lognormal	 distribution.	 Using	 the	 program	 Lognorm4	
(Strom	&	Stansbury,	2000),	or	after	coding	the	relevant	equations	in	Excel,	Systat	13,	or	SAS	9.3,	
we	 determined	 the	 lognormal	 distribution	 using	 any	 two	 published	 values	 of	 the	 arithmetic	
standard	deviation,	mean,	median,	minimum,	or	maximum,	or	the	arithmetic	95%	CI.			
Simulated	dataset	generation		
The	 summary	 statistics	 for	 the	 lognormal	 distribution	 of	 a	 particular	 hormone,	 in	 a	
specific	 study,	were	 used	 to	 create	 a	 random	 sample	 of	 the	 same	 size,	 log-mean,	 and	 log-SD	
reported	 in	 the	 study.	When	 the	 size	 of	 the	 sample	 from	 the	 specific	 study	 for	 the	 particular	
hormone	 was	 sufficiently	 large	 (arbitrarily	 ≥20),	 the	 distribution	 of	 the	 random	 logarithmic	
values	was	checked	for	outliers	and	other	departures	from	normality	using	probability	plots.	The	
underlying	assumption	for	pooling	data	from	different	studies	is	that	because	animals	used	in	a	
study	 is	 a	 random	 sample	 from	 the	 population	 of	 the	 selected	 strain,	 the	 summary	 statistics	
from	 all	 publications	 describe	 random	 samples	 from	 the	 same	 underlying,	 but	 unknown,	
lognormal	distribution	for	each	hormone.	Therefore,	the	simulated	logarithmic	values	compiled	
from	all	samples	from	all	studies	are	expected	to	have	a	normal	distribution.	Custom-designed	
programs	created	in	SAS	9.3	were	used	to	carry	out	the	simulations.	
	
Data	analysis	
The	set	of	all	the	random	samples	for	each	hormone	separately	was	analyzed	using	the	
generalized	linear	mixed	model	procedure,	GLIMMIX	(SAS	9.4),	to	determine	the	extent	to	which	
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kit	(radioimmunoassay,	“RIA”;	ELISA,	“EIA”),	tissue	(serum,	”S”;	plasma,	“P”),	strain	(Long-Evans,	
“LE”;	 Sprague-Dawley,	 “SD”,	 Wistar,	 “W”),	 age	 (neonatal,	 pre-weaning,	 prepubertal,	 adult,	
aging),	and	sex	(male	or	female)	affected	the	mean	level	of	each	hormone.	All	variables	 in	the	
model	were	 fixed	 independent	 factors	 (i.e.,	were	 chosen	 by	 the	 original	 researcher	 and	were	
specified	in	the	inclusion	criteria).	A	random	variable,	Paper	ID,	designated	the	random	values	as	
repeated	measures	 (rats	within	 study).	 Interactions	 retained	 in	 the	model	were	 age	 category	
within	 sex	 “AGE_CAT(SEX),”	 age	 category	 within	 strain	 “AGE_CAT(STRAIN),”	 strain	 by	 sex	
“STRAIN*SEX,”	and	age	category	within	sex	by	strain	“AGE_CAT(SEX*STRAIN).”	Age	category	was	
a	 nested	 factor,	 rather	 than	 crossed,	 because	 some	 age	 categories	 were	 not	 found	 during	
literature	 review	 for	both	 sexes	and	all	 strains.	 Four	F	 test	methods	 (Tukey’s	HSD,	Hochberg’s	
step-up	Bonferroni,	Holm’s	step-down	Bonferroni,	and	False	Discovery	Rate)	to	adjust	p-values	
for	multiple	comparisons	were	compared.	Adjusted	P-values	for	all	effects	are	in	the	tables	and	
p-values	 are	 in	 the	 text	 by	 adjustment	method.	 Residuals	 from	 the	ANOVA	were	 checked	 for	
normality	using	probability	and	quartile-quartile	(Q-Q)	plots,	and	histograms.		
	
Results 
	
Kit	and	Tissue	Effect	
Main	 effects	 for	 kit	 were	 non-significant	 for	 estradiol,	 progesterone,	 and	 testosterone	
(Tables	1,	2).	Main	effects	and	pairwise	comparisons	for	tissue	were	significant	for	progesterone	
and	testosterone,	but	not	for	estradiol	(Tables	1,	3).	
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Sex	Effect	
Pairwise	comparisons	were	not	estimable	for	any	interaction	that	included	age	category	
due	to	multiple	missing	combinations	(Table	15,	Figure	22).	For	the	same	reason,	sex	differences	
by	strain	averaged	over	all	age	categories	were	not	estimable	for	all	three	hormones.	
	
Estradiol:		
The	 main	 effect	 of	 sex	 for	 estradiol	 was	 not	 significant	 (p	 =	 0.055);	 however,	 the	
interactions	of	sex	(within	age	category,	averaged	over	all	strains)	and	sex	(by	strain,	within	age-
category)	were	significant	(p	<	0.0001,	p	=	0.0084,	respectively)	(Table	4).	The	interaction	of	sex	
(by	strain,	averaged	over	all	age	categories)	was	not	significant	(p	=	0.11)	(Table	4).	
Pairwise	differences	of	estradiol	between	males	and	females	within	the	prepubertal	age	
category	 (averaged	 over	 all	 strains)	 was	 significant,	 with	 males	 having	 higher	 estradiol	 than	
females	 (Holm,	Hoch,	FDR	p	=	0.027)	 (Table	5,	Figure	1).	Comparisons	of	sex	 for	 the	neonatal,	
preweaning,	and	aging	categories	could	not	be	estimated.	
Significant	 pairwise	 differences	 in	 estradiol	 were	 found	 between	 males	 and	 females	
(within	age	category,	by	strain),	in	which	adult	females	had	higher	estradiol	than	males	for	adult	
Long-Evans	(Holm	p	=	0.014;	Hoch	p	=	0.014;	FDR	p	=	0.013),	and	vice	versa	for	neonatal	Wistar	
(Holm,	Hoch	p	=	0.023;	FDR	p	=	0.013)	and	prepubertal	Sprague-Dawley	(FDR	p	=	0.038)	(Table	6,	
Figure	4).	 The	 inconsistency	between	 the	 significant	main	 interaction	of	 sex	 and	age	 category	
and	the	non-significance	of	pairwise	comparisons	within	the	interaction	is	due	to	the	adjustment	
of	p-values	for	the	pairwise	comparisons.	Comparisons	of	sex	for	the	Long-Evans	neonatal	and	
preweaning	age	categories	could	not	be	estimated.	
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Progesterone:	
For	progesterone,	 the	main	effect	 for	sex	was	not	statistically	significant	 (p	=	0.17)	but	
the	interaction	of	sex	within	age	category	averaged	over	all	strains,	was	significant	(p	=	0.0007)	
(Table	4).	The	interaction	of	sex	by	strain	averaged	over	all	age	categories,	and	the	interaction	of	
sex	by	strain	within	age-category,	were	not	significant	(p	=	0.11,	p	=	0.35,	respectively)	(Table	4).	
For	 pairwise	 comparisons,	 progesterone	 concentrations	 differed	 significantly	 between	
sexes	within	each	age	category	averaged	over	all	 strains,	with	 female	adults	higher	 than	male	
adults	(Tukey	p	=	0.027;	Holm,	Hoch,	FDR	p	=	0.002)	(Table	5,	Figure	2).	Comparisons	of	sex	for	
the	neonatal,	preweaning,	and	aging	categories	could	not	be	estimated.	
There	were	significant	pairwise	differences	between	sexes	within	each	age	category,	by	
strain,	 in	 which	 female	 adult	 Sprague-Dawley	 had	 higher	 estradiol	 levels	 than	 male	 adult	
Sprague-Dawley	 (Holm,	 Hoch,	 FDR	 p	 =	 0.008)	 (Table	 6,	 Figure	 5).	 Comparisons	 of	 sex	 for	 the	
Long-Evans	neonatal	and	preweaning	age	categories	could	not	be	estimated	due	to	insufficient	
data.	
	
Testosterone:	
The	 main	 effect	 of	 sex	 for	 testosterone	 was	 significant	 (p	 <	 0.0001),	 as	 well	 as	
interactions	of	 sex	within	age	category	averaged	over	all	 strains	 (p	=	0.033),	and	sex	by	strain	
within	age	category	(p	<	0.0001),	but	not	 for	the	 interaction	of	sex	by	strain	averaged	over	all	
age	categories	(p	=	0.31)	(Table	4).	
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Pairwise	 differences	 of	 testosterone	 between	males	 and	 females	 within	 age	 category,	
averaged	over	 all	 strains,	were	 significant	 for	 adults,	with	males	 greater	 than	 females	 (Tukey,	
Holm,	Hoch,	 FDR	p	 <	 0.0001)	 (Table	 5,	 Figure	 3).	 Comparisons	within	 all	 other	 age	 categories	
could	be	estimated.	
All	pairwise	differences	of	testosterone	between	males	and	females	within	age	category,	
by	strain,	were	significant,	with	males	higher	than	females	 in	all	cases	(all	Hoch,	FDR	p	<	0.04)	
(Table	6,	Figure	6).	Comparisons	of	sex	for	Long-Evans	could	not	be	estimated	for	the	neonatal	
and	preweaning	age	categories,	and	Wistar	could	only	be	estimated	for	adults.	
	
Age	Effect	
Pairwise	 comparisons	were	not	estimable	 for	any	 interaction	 that	 included	 the	 “aging”	
category	due	to	insufficient	numbers	of	values.		
	
Estradiol:	
The	main	effect	of	 age	 category	 for	 estradiol	was	 significant	 (p	<	0.0001),	 as	were	 the	
interactions	of	sex	within	age	category,	averaged	over	all	strains	(p	<	0.0001),	and	strain	within	
age	category,	averaged	over	both	sexes	(p	=	0.0084)	(Table	4).	The	interaction	of	sex	by	strain,	
within	age	category,	was	not	significant	(p	=	0.23)	(Table	4).	
Pairwise	differences	of	estradiol	between	age	categories	averaged	over	both	sexes	and	
all	 strains	 were	 all	 significant,	 but	 could	 only	 be	 estimated	 for	 the	 comparison	 of	 neonatal-
preweaning	 (p	 =	 0.0007)	 and	prepubertal-adult	 (p	 <	 0.0001)	 (Table	 7).	 The	 preweaning	 group	
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had	 higher	 estradiol	 levels	 than	 the	 neonatal	 group,	 and	 the	 prepubertal	 group	 had	 higher	
estradiol	levels	than	the	adult	group.	
Pairwise	comparisons	of	age	categories	for	females	averaged	over	all	strains	reported	the	
preweaning	 group	 had	 significantly	 higher	 estradiol	 than	 the	 neonatal	 age	 group	 (Tukey	 p	 <	
0.0001;	Holm	p	=	0.0004;	Hoch	p	=	0.0002;	FDR	p	=	0.00013),	and	 the	prepubertal	group	had	
significantly	higher	estradiol	than	the	adult	age	group	(Tukey	p	<	0.0001;	Holm	p	=	0.0004;	Hoch	
p	 =	 0.0002;	 FDR	 p	 =	 0.00013)	 (Table	 8,	 Figure	 7).	 For	males,	 the	 prepubertal	 group	 also	 had	
significantly	higher	estradiol	than	the	adult	group	(Tukey	p	<	0.0001;	Holm	p	=	0.0004;	Hoch	p	=	
0.0002;	 FDR	 p	 =	 0.00013).	 The	 only	 other	 comparison	 that	 could	 be	 estimated	was	 between	
male	neonatal	and	preweaning	groups,	and	this	comparison	was	not	significant	(Tukey	p	=	0.69;	
Holm,	Hoch,	FDR	p	=	0.0901)	(Table	8).	
Significant	pairwise	differences	between	age	categories	within	sex	by	strain	were	found	
between	the	majority	of	pairings	of	age	categories,	for	at	least	one	strain	per	pairing,	except	for	
the	comparison	of	male	neonatal	and	prepubertal	age	groups	(SD:	all	adjusted	p	>	0.5;	Wistar:	all	
adjusted	p	 >	 0.3)	 and	male	preweaning	 and	prepubertal	 age	 groups	 (SD:	 all	 adjusted	p	 >	 0.8;	
Wistar:	 all	 adjusted	p	>	0.2)	 (Table	10,	 Figure	13).	 Except	 for	 the	 comparisons	of	prepubertal-
adult,	and	prepubertal-aging	female	age	categories,	comparisons	of	age	categories	for	the	Long-
Evans	 strain	 could	 not	 be	 estimated.	 Overall,	 there	 were	 significantly	 higher	 estradiol	 levels	
during	prepuberty	 than	adulthood	 for	all	 strains	and	 in	both	sexes,	except	 for	 female	Wistars.	
Although	 the	 comparison	of	 neonatal	 and	preweaning	 age	 groups	 could	not	 be	 estimated	 for	
Long-Evans,	 there	 were	 significantly	 higher	 estradiol	 levels	 during	 the	 preweaning	 versus	
neonatal	period	for	all	strains	and	in	both	sexes,	except	for	male	Wistar	rats.	
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Progesterone:	
The	main	effect	of	age	category	 for	progesterone	was	significant	 (p	<	0.0001),	as	were	
the	 interactions	 of	 sex	 within	 age	 category	 averaged	 over	 all	 strains	 (p	 =	 0.0007),	 and	 strain	
within	age	category	averaged	over	both	sexes	(p	=	0.0002)	(Table	4).	The	 interaction	of	sex	by	
strain	within	age	category	was	not	significant	(p	=	0.35)	(Table	4).	
Pairwise	differences	of	progesterone	between	age	categories	averaged	over	both	sexes	
and	all	strains	were	significant	for	the	comparison	of	neonatal-preweaning	(p	=	0.041),	but	not	
for	prepubertal-adult	(p	=	0.73)	(Table	7).	All	other	age	comparisons	could	not	be	estimated.	The	
preweaning	group	had	higher	estradiol	than	the	neonatal	group.	
There	 were	 no	 significant	 pairwise	 differences	 between	 age	 categories	 within	 sex	
averaged	 over	 all	 strains	 (all	 p	 >	 0.2)	 (Table	 8,	 Figure	 8).	 Only	 comparisons	 of	 neonatal-
preweaning,	 prepubertal-adult,	 prepubertal-aging,	 and	 adult-aging	 could	 be	 estimated	 for	
females,	and	only	neonatal-preweaning	and	prepubertal-adult	could	be	estimated	for	males.	
Significant	pairwise	differences	between	age	categories	within	sex	by	strain	were	found	
between	the	majority	of	pairings	of	age	categories	for	females,	for	at	least	one	strain	per	pairing	
(all	p	<	0.02)	 (Table	10,	Figure	14).	Overall,	progesterone	significantly	 increased	with	age	until	
adulthood.	Except	for	the	pairings	involving	any	two	combinations	of	the	prepubertal,	adult,	or	
aging	categories,	comparisons	of	age	categories	for	the	Long-Evans	strain	could	not	be	estimated	
for	females.	Pairwise	differences	between	age	categories	within	sex	by	strain	were	found	with	
the	neonatal	group	having	significantly	lower	progesterone	than	all	other	age	categories,	except	
for	aging	(which	could	not	be	estimated)	for	Sprague-Dawley	only	in	males	(all	p	<	0.04)	(Table	
		 29	
10,	 Figure	 14).	 Long-Evans	 age	 comparisons	 could	 only	 be	 estimated	 for	 the	 comparison	 of	
prepubertal-adult	in	males.		
	
Testosterone:	
The	main	effect	of	age	category	for	testosterone	was	significant	(p	<	0.0001),	as	were	the	
all	 interactions	 involving	 age	 category,	 including	 sex	 within	 age	 category	 averaged	 over	 all	
strains)	(p	=	0.033),	strain	within	age	category	averaged	over	both	sexes	(p	<	0.0001),	and	sex	by	
strain	within	age	category	(p	<	0.0001)	(Table	4).	
None	of	the	pairwise	differences	of	testosterone	between	age	categories	averaged	over	
both	sexes	and	all	strains,	or	pairwise	differences	between	age	categories	by	sex	averaged	over	
all	strains,	could	be	estimated	(Table	7,	Table	8).		
For	 females,	 significant	 pairwise	 differences	 between	 age	 categories	 by	 sex	 by	 strain,	
were	found	between	the	majority	of	pairings	of	age	categories,	for	at	least	one	strain	per	pairing	
(all	 p	 <	 0.006)	 (Table	 10,	 Figure	 15),	 except	 for	 neonatal-adult	 (p	 =	 0.070).	 Except	 for	 the	
prepubertal-aging	 and	 adult-aging,	 comparisons	 of	 age	 categories	 for	 the	 Long-Evans	 strain	
could	 not	 be	 estimated	 for	 females.	 Wistar	 comparisons	 could	 only	 be	 estimated	 for	
preweaning-prepubertal,	preweaning-adult,	and	prepubertal-adult	for	females.		
For	males,	significant	pairwise	differences	between	age	categories	by	sex	by	strain,	were	
found	between	neonatal-prepubertal	 (Long-Evans)	 (all	p	<	0.003),	neonatal-prepubertal	 (Long-
Evans	 and	 Sprague-Dawley)	 (all	 p	 <	 0.003),	 and	 prepubertal-adult	 (Long-Evans	 and	 Sprague-
Dawley)	(all	p	<	0.003)	(Table	10,	Figure	15).	Comparisons	involving	the	aging	category	could	not	
be	estimated.	Comparisons	of	within	the	Wistar	strain	could	not	be	estimated	for	any	pairing	of	
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age	 categories,	 and	 within	 the	 Long-Evans	 strain	 could	 only	 be	 estimated	 for	 neonatal-
prepubertal,	neonatal-adult,	and	prepubertal-adult	for	males.			
Strain	Effect	
Estradiol:	
The	 main	 effect	 of	 strain	 for	 estradiol	 was	 not	 significant	 (p	 =	 0.097)	 (Table	 4).	 The	
interaction	of	strain	by	sex	averaged	over	all	age	categories,	and	the	interaction	of	sex	by	strain	
within	 age	 category,	 were	 not	 significant	 (p	 =	 0.11,	 p	 =	 0.23,	 respectively).	 However,	 the	
interaction	of	strain	within	age	category	averaged	over	both	sexes	was	significant	(p	=	0.0084).		
Pairwise	differences	of	estradiol	between	 strains	averaged	over	both	 sexes	and	all	 age	
categories	 could	only	be	estimated	 for	 the	 comparison	of	 Sprague-Dawley	with	Wistar,	which	
was	not	significant	(p	=	0.64)	(Table	11).	Pairwise	differences	of	estradiol	between	strains	by	sex	
averaged	over	 all	 age	 categories	 could	 only	 be	 estimated	 for	 the	 comparison	 of	 the	 Sprague-
Dawley	 with	 Wistar	 strains	 for	 males	 and	 females.	 Only	 the	 comparison	 of	 female	 Sprague-
Dawley	with	Wistar	rats	was	significant	(Tukey:	p	=	0.088;	Holm,	Hoch,	and	FDR:	p	=	0.038),	with	
estradiol	levels	higher	in	the	Sprague-Dawley	than	Wistar	strain	(Table	12).	
For	 females,	pairwise	comparisons	of	strain	within	age	category	by	sex	were	significant	
between	the	Sprague-Dawley	and	Wistar	strains,	with	the	Sprague-Dawley	strain	having	higher	
estradiol	levels	than	the	Wistar	strain	in	the	neonatal	and	preweaning	periods	(all	adjusted	p	<	
0.05)	 (Table	14,	Figure	19).	During	adulthood,	 the	Sprague-Dawley	strain	also	had	significantly	
higher	estradiol	than	Long-Evans	strain	(only	for	the	False	Discovery	Rate,	p	=	0.025).	The	Wistar	
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strain	also	had	significantly	higher	estradiol	 levels	 than	 the	Long-Evans	 strain	 (all	 adjusted	p	<	
0.04).	
For	 males,	 pairwise	 comparisons	 of	 strain	 within	 age	 category	 by	 sex	 were	 similar	 to	
females	 in	 that	 both	 the	 Sprague-Dawley	 and	Wistar	 strains	 estradiol	 levels	were	 significantly	
higher	than	in	the	Long-Evans	strain	(only	for	the	False	Discovery	Rate,	SD-LE:	p	=	0.025,	W-LE:	p	
=	0.040).	For	both	males	and	females,	pairwise	comparisons	were	not	estimable	for	any	pairing	
that	 involved	 the	aging	 category.	 Strain	 comparisons	within	 the	neonatal	 and	preweaning	age	
categories	could	only	be	estimated	for	the	comparison	of	Sprague-Dawley	with	Wistar	strains.	
	
Progesterone:	
The	main	effect	of	 strain	 for	progesterone	was	not	 significant	 (p	=	0.99)	 (Table	4).	The	
interaction	of	strain	by	sex	averaged	over	all	age	categories	and	the	interaction	of	sex	by	strain	
within	 age	 category	 were	 not	 significant	 (p	 =	 0.13,	 p	 =	 0.35,	 respectively).	 However,	 the	
interaction	of	strain	within	age	category	averaged	over	both	sexes	was	significant	(p	=	0.0002).		
	 Pairwise	differences	of	progesterone	between	strains	averaged	over	both	sexes	and	all	
age	categories,	and	pairwise	differences	between	strains	by	sex	averaged	over	all	age	categories,	
could	not	be	estimated	(Table	11,	Table	12).	
	 No	 significant	pairwise	differences	were	 found	between	 strains	within	 age	 category	by	
sex	(Table	14,	Figure	20).	Comparisons	within	the	neonatal	and	preweaning	age	categories	could	
only	 be	 estimated	 for	 the	 comparison	 of	 Sprague-Dawley	 and	 Wistar	 strains	 for	 males	 and	
females.	Comparisons	within	the	aging	group	could	only	be	estimated	for	females.	
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Testosterone:	
The	main	 effect	 of	 strain	 for	 testosterone	was	not	 significant	 (p	 =	 0.81)	 (Table	 4).	 The	
interaction	 of	 strain	 by	 sex	 averaged	 over	 all	 age	 categories	 was	 not	 significant	 (p	 =	 0.32),	
However,	 the	 interaction	 of	 strain	 within	 age	 category	 averaged	 over	 both	 sexes,	 and	 the	
interaction	of	strain	within	age	category	by	sex,	were	significant	(both	p	<	0.0001).			
	 Pairwise	 differences	 of	 testosterone	between	 strains	 averaged	over	 both	 sexes	 and	 all	
age	categories,	and	pairwise	differences	between	strains	by	sex	averaged	over	all	age	categories,	
could	not	be	estimated	(Table	11,	Table	12).	
For	 females,	pairwise	comparisons	of	strain	within	age	category	by	sex	were	significant	
between	the	Sprague-Dawley	and	Wistar	strains,	with	the	Sprague-Dawley	strain	having	higher	
testosterone	 levels	 than	 the	 Wistar	 strain	 during	 the	 prepubertal	 period	 (only	 for	 the	 False	
Discovery	Rate,	p	=	0.038)	(Table	14,	Figure	21).	Significant	differences	were	found	between	the	
Long-Evans	and	Sprague-Dawley	strains,	with	Sprague-Dawley	having	higher	testosterone	levels	
during	 prepuberty	 (only	 for	 the	 False	Discovery	 Rate,	 p	 =	 0.044),	 and	with	 Long-Evans	 having	
higher	 testosterone	 during	 adulthood	 (only	 for	 the	 False	 Discovery	 Rate,	 p	 =	 0.032).	
Comparisons	within	the	preweaning	age	category	could	only	be	estimated	for	the	comparison	of	
the	 Sprague-Dawley	 	 with	 Wistar	 strains.	 Pairwise	 comparisons	 were	 not	 estimable	 for	 the	
neonatal	or	aging	categories.	
For	males,	pairwise	comparisons	of	strain	(within	age	category,	by	sex)	were	significant	
between	 the	 Sprague-Dawley	 and	Wistar	 strains,	 with	Wistar	 rats	 having	 higher	 testosterone	
levels	 than	 Sprague-Dawley	 males	 during	 the	 adult	 period	 (all	 adjusted	 p	 <	 0.02)	 (Table	 14,	
Figure	 21).	 Significant	 differences	 were	 found	 between	 the	 Long-Evans	 and	 Sprague-Dawley	
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strains,	 with	 the	 Sprague-Dawley	 strain	 having	 the	 higher	 testosterone	 levels	 during	 the	
neonatal	 period	 (only	 for	 the	 False	Discovery	Rate,	 p	 =	 0.032).	 The	 Long-Evans	 strain	had	 the	
higher	testosterone	levels	during	prepuberty	(only	for	the	False	Discovery	Rate,	p	=	0.038).	The	
Wistar	 strain	 had	 significantly	 higher	 testosterone	 levels	 than	 the	 Long-Evans	 strain	 during	
adulthood	 (only	 for	 the	 False	 Discovery	 Rate,	 p	 =	 0.042).	 Pairwise	 comparisons	 within	 the	
neonatal	 and	 prepubertal	 age	 categories	 could	 only	 be	 estimated	 for	 the	 comparison	 of	 the	
Long-Evans	 with	 Sprague-Dawley	 strains,	 and	 no	 comparisons	 could	 be	 estimated	 for	 the	
preweaning	or	aging	categories.	
	
Discussion	
In	 the	 study	 of	 reproductive	 toxicology,	 one	 of	 the	 greatest	 difficulties	 is	 establishing	
reproducible	 results	 for	 a	 chemical	 of	 interest.	 The	 controversy	over	 the	 contradictory	 results	
obtained	by	 different	 laboratory	 groups	 can	 potentially	 be	 traced	 to	 differences	 in	 laboratory	
technique,	 experimental	 subjects,	 and	other	 aspects	of	 experimental	 design.	 In	particular,	 the	
chemical	 bisphenol-A	 has	 established	 itself	 as	 one	 of	 these	 controversial	 chemicals	 in	 recent	
years.	 Kwon,	 et	 al.,	 (2000),	 who	 conducted	 a	 BPA	 study	 on	 development	 and	 reproductive	
function,	posited	an	interesting	point	by	stating	that	one	of	the	factors	that	may	have	affected	
their	results	could	be	the	choice	in	strain	of	their	rodent	model,	and	“due	to	the	insensitivity	of	
Sprague-Dawley	rats	 to	endocrine-mediated	toxicity	by	endocrine	modulators.”	However,	 they	
further	 elaborated	 that	 this	 potential	 for	 strain-related	 differences	 in	 susceptibility	 is	 under-
characterized,	and	 that	genetically	mediated	mechanisms	of	endocrine	 toxicity	have	yet	 to	be	
clearly	defined.	In	addition	to	acknowledging	interspecies	differences	in	the	study	of	endocrine	
disruption,	 laboratories	must	also	 consider	 the	 susceptibility	of	 a	particular	 genotype	within	a	
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species.	 While	 much	 of	 the	 functional	 activity	 of	 sex	 hormones	 has	 been	 studied	 and	
established,	hormonal	sensitivity	and	the	factors	governing	differences	within	a	population	have	
received	less	attention	(Spearow,	et	al.,	1999).	To	characterize	genotypic	susceptibility	profiles,	
one	can	begin	by	describing	the	traits	attributable	to	a	particular	strain	in	comparison	to	others.	
In	this	instance,	we	investigated	strain	differences	in	steroidal	sex	hormone	levels	with	respect	
to	sex	and	age.	
As	expected,	there	were	significant	sex	and	age	differences	in	hormone	levels.	Males	had		
higher	 levels	 of	 testosterone	 at	 all	 ages	 and	 in	 several	 strains	 (Table	 6).	 Sex	 differences	 in	
estradiol	were	 less	prominent,	 though	adult	 females	had	higher	estradiol	 than	males	within	at	
least	one	strain,	while	males	had	higher	estradiol	within	the	age	groups	prior	to	puberty.	There	
was	little	difference	between	sexes	in	progesterone,	except	within	the	adult	age	category	when	
females	began	to	show	higher	levels	than	males.	Age	differences	in	all	hormones	were	present:		
estradiol	 appeared	 to	 increase	 after	 the	 neonatal	 period	 and	 then	 dropped	 after	 puberty	 in	
females	(Table	8).	This	seems	contradictory	to	what	 is	known	about	the	role	of	rising	estradiol	
that	occurs	during	puberty	in	females,	although	the	influence	of	estrous	cycle	may	have	played	a	
part	 in	 this	 discovery,	 as	 estrous	 cycle	 stage	 of	 adult	 females	 was	 captured	 during	 data	
compilation	 (when	 given)	 but	 was	 not	 included	 in	 the	 model	 in	 this	 preliminary	 analysis	 (to	
accommodate	 missing	 data).	 Future	 evaluation	 of	 the	 data	 could	 and	 should	 take	 into	
consideration	the	particular	stage	within	the	estrous	cycle	from	which	the	measurements	were	
taken.	Progesterone	and	testosterone	both	seemed	to	increase	steadily	with	age	for	both	sexes,	
with	 the	 exception	 of	 a	 dip	 in	 female	 testosterone	 occurring	 between	 the	 preweaning	 and	
prepubertal	periods	(Table	10).	
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Our	analysis	showed	no	differences	between	the	popular	outbred	strains	of	Long-Evans,	
Wistar,	 or	 Sprague-Dawley	 in	 the	 levels	 of	 circulating	 progesterone	 at	 any	 age	 (Table	 14).	 In	
contrast,	circulating	levels	of	estradiol	in	the	Long-Evans	strain	appeared	to	be	lower	than	both	
Sprague-Dawley	and	Wistar	 strains	 for	both	male	and	 female	adult	 animals	 (Table	14).	 This	 is	
consistent	 with	 the	 findings	 of	 O’Connor,	 et	 al.,	 (1999),	 who	 found	 that	 serum	 estradiol	 was	
significantly	greater	 for	Sprague-Dawley	 rats	compared	 to	Long-Evans	 rats.	Female	Wistar	 rats	
also	 had	 less	 estradiol	 than	 young	 (neonatal	 and	 preweaning)	 Sprague-Dawley	 rats.	
Accordingly—although	the	study	was	conducted	in	adult	animals—female	Wistar	rats	were	more	
sensitive	to	the	uterine	proliferating	effects	of	ethinyl	estradiol	than	Sprague-Dawley	rats	(Diel,	
et	 al.,	 2001),	 which	 may	 be	 explained	 by	 the	 larger	 pool	 of	 estradiol	 available	 to	 buffer	 the	
effects	of	exogenous	estrogenic	compounds	in	Sprague-Dawley	rats.		
Interestingly,	 Sprague-Dawley	 rats	 of	 both	 sexes	 had	 higher	 testosterone	 levels	 than	
Long-Evans	 rats	 early	 on	 (female	 prepubertal	 rats,	 and	 male	 neonatal	 rats),	 but	 this	 strain	
difference	 flipped	 as	 the	 animals	 aged:	when	 females	 reached	 adulthood,	 and	males	 reached	
pre-puberty,	 Long-Evans	 rats	 had	 higher	 amounts	 of	 testosterone	 than	 Sprague-Dawley	 rats	
(Table	14).	Anogenital	distance	at	PND	2	was	 found	to	be	slightly	 less	 (~	1mm)	for	male	Long-
Evans	rats	compared	to	Sprague-Dawley	rats,	which	supports	our	finding	that	these	animals	had	
less	 testosterone	 at	 young	 ages	 because	 shorter	 anogenital	 distance	 is	 an	 indicator	 of	
feminization	 and	 lower	 androgen	 levels	 (You,	 et	 al.,	 1998).	 Furthermore,	 the	 Sprague-Dawley	
rats	in	this	study	were	less	susceptible	than	the	Long-Evans	rats	to	the	anogenital-distance-	and	
seminal-vesicle-weight-reducing	effects	of	androgen	antagonist,	p,p’-DDE.	The	strain	difference	
also	depended	on	the	sex	of	the	animal,	as	male	Wistar	rats	had	higher	testosterone	than	both	
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Sprague-Dawley	 and	 Long-Evans	 strains,	 but	 female	Wistar	 rats	 had	 lower	 testosterone	 levels	
than	 the	 Sprague-Dawley	 strain.	Wilkinson,	 et	 al.,	 (2000),	 reported	 that	male	Wistar	 rats	 had	
significantly	larger	testes	relative	to	body	weight	than	Sprague-Dawley	rats,	consistent	with	our	
finding	that	these	animals	also	had	higher	testosterone	levels,	although	the	Sprague-Dawley	rats	
had	 larger	 seminal	 vesicles,	 an	 organ	 in	 which	 development,	 size,	 and	 maintenance	 are	
dependent	on	androgens.	
	
Conclusions	
These	analyses	 indicate	that	there	are	apparent	differences	 in	hormone	levels	between	
the	 commonly	 utilized	 Sprague-Dawley,	Wistar,	 and	 Long-Evans	 strains,	 and	 that	 these	 strain	
differences	 are	 also	 dependent	 on	 the	 animal’s	 sex	 and	 age.	What	mechanisms	 underlie	 the	
cause	of	these	strain	differences	should	be	a	topic	of	 further	genetic	evaluation.	Hypothesized	
mechanisms	 have	 already	 been	 proposed	 such	 as	 differences	 in	 the	 speed	 and	 efficiency	 of	
pharmacokinetic	metabolism	 (You,	et	al.,	 1998;	O’Connor,	et	al.,	 1999;	Spearow,	et	al.,	 1999),	
alternate	 activation	 of	 hormonally	 responsive	 genes	 (Long,	 et	 al.,	 2000),	 and	 steroidogenesis	
and/or	 gonadotropin	 secretion	 rates	 (Spearow,	 et	 al.,	 1999).	 However,	 these	 proposed	
mechanisms	are	likely	to	be	dependent	on	tissue	type.	
Significant	strain-specific	sensitivity	to	sex-hormone	agonists	and	antagonists	and	other	
endocrine-disrupting	chemicals	have	already	been	established	with	regard	to	other	reproductive	
parameters	in	addition	to	sex	hormone	levels	(Howdeshell,	et	al.,	2008;	Bailey	&	Nephew,	et	al.,	
2002;	Pandey,	et	al.,	2005;	Long,	et	al.,	2000;	Wilkinson,	et	al.,	2000;	Steinmetz,	et	al.,	1997;	You,	
et	al.,	1998;	Tyl,	et	al.,	2002;	O’Connor,	et	al.,	1999).	Thus,	care	must	be	taken	 in	toxicological	
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assessments	to	consider	the	traits	of	any	particular	strain	before	comparison	with	other	rodent	
studies,	and	with	human	populations.	Future	studies	providing	information	on	strain	differences	
in	various	reproductive	measurements	combined	with	knowledge	of	strain-specific	differences	in	
susceptibility	to	endocrine-mediated	toxicity	will	enhance	our	understanding	of	the	mechanisms	
by	which	a	toxicant	affects	an	animal’s	physiology.	
It	 is	 appropriate	 to	 conclude	 with	 a	 word	 of	 caution:	 some	 of	 the	 “not	 significant”	
statistical	differences	are	due	to	small	sample	sizes	for	some	combinations	of	the	independent	
variables.	The	statistical	analysis	reports	these	as	“not	estimable,”	which	is	not	the	same	as	“not	
significant”	 and	 “inestimable	 given	 a	 larger	 sample.”	 	 Statements	 of	 “not	 significant”	 deriving	
from	sample	 characteristics	must	be	distinguished	 from	“not-significant”	due	 to	differences	 in	
hormone	 levels	 that	 are	 truly	 small.	 	 The	 overall	 caveat	 is	 that	 “not	 significant,”	 as	 for	
“significant,”	applies	to	the	statistical	properties	of	the	data	used	in	the	analysis,	which	may	or	
may	not	reflect	the	biological	consequences	of	such	differences,	overall	(for	the	“sample”)	and	
for	the	individual	animals	comprising	the	sample.		
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Tables	
Table	1.		Kit	and	Tissue	Main	Effects:		Type	III	Tests	of	Fixed	Effects	
	
	 Effect	 Num	DF	 Den	DF	 F	Value	 Pr	>	F	
E2	 KIT	 1	 3139	 0.02	 0.87	TISSUE	 1	 3139	 0.00	 0.98	
P4	 KIT	 1	 3326	 0.20	 0.65	TISSUE	 1	 3326	 20.2	 *<0.0001	
T	 KIT	 1	 2982	 1.11	 0.29	TISSUE	 1	 2982	 12.5	 *0.0004	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	critical	value,	alpha	=	0.05.		
Table	2.	Differences	of	Kit	LSMs	(EIA	vs.	RIA)	
	
	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	 Adj	P	
(Tukey)	
E2	 -0.0383	 0.249	 3139	 -0.15	 0.88	 0.87	
P4	 0.169	 0.378	 3326	 0.45	 0.66	 0.65	
T	 0.126	 0.120	 2982	 1.06	 0.29	 0.29	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	Tukey-adjusted	p-value,	“Adj	P,”	alpha	=	0.05.		
Table	3.	Differences	of	Tissue	LSMs	(Plasma	vs.	Serum)		
	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	 Adj	P	
(Tukey)	
	
E2	 -0.00338	 0.252	 3139	 -0.01	 0.99	 0.98	 	
P4	 -0.645	 0.144	 3326	 -4.49	 <.0001	 *<0.0001	 S	>	P	
T	 0.466	 0.132	 2982	 3.53	 0.0004	 *0.0004	 P	>	S	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	Tukey-adjusted	p-value,	“Adj	P,”	alpha	=	0.05.		
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Table	4.		Sex,	Strain,	and	Age	Main	Effects	and	Interactions:		Type	III	Tests	of	Fixed	Effects	
	
	 Effect	 Num	DF	 Den	DF	 F	Value	 Pr	>	F	
E2	
SEX	 1	 3139	 3.69	 0.055	
STRAIN	 2	 3139	 2.34	 0.097	
AGE_CAT	 4	 3139	 26.3	 *<.0001	
STRAIN*SEX	 2	 3139	 2.19	 0.11	
AGE_CAT(SEX)	 3	 3139	 7.13	 *<0.0001	
AGE_CAT(STRAIN)	 4	 3139	 3.43	 *0.0084	
AGE_CAT(STRAIN*SEX)	 4	 3139	 1.41	 0.23	
P4	
SEX	 1	 3326	 1.92	 0.17	
STRAIN	 2	 3326	 0.01	 0.99	
AGE_CAT	 4	 3326	 17.9	 *<0.0001	
STRAIN*SEX	 2	 3326	 2.05	 0.13	
AGE_CAT(SEX)	 3	 3326	 5.72	 *0.0007	
AGE_CAT(STRAIN)	 6	 3326	 4.43	 *0.0002	
AGE_CAT(STRAIN*SEX)	 4	 3326	 1.12	 0.35	
T	
SEX	 1	 2982	 65.8	 *<0.0001	
STRAIN	 2	 2982	 0.21	 0.81	
AGE_CAT	 4	 2982	 68.3	 *<0.0001	
STRAIN*SEX	 2	 2982	 1.16	 0.31	
AGE_CAT(SEX)	 3	 2982	 2.92	 *0.033	
AGE_CAT(STRAIN)	 4	 2982	 20.0	 *<0.0001	
AGE_CAT(STRAIN*SEX)	 1	 2982	 35.5	 *<0.0001	
Separate	analyses	run	by	hormone.	Analyses	were	run	simultaneously	with	effects	listed	in	Table	1,	according	to	respective	hormones.	
*statistically	significant	according	to	critical	value,	alpha	=	0.05.	
	
Table	5.		Sex	Effect:		Differences	of	AGE_CAT(SEX)	LSMs	(Female	vs.	Male)		
	
	 Age	 Estimate	 SE	 DF	 t	Value	 Pr	>	|t|	 Adj	P	
(Tukey)	
Adj	P	
(Holm)	
Adj	P	
(Hoch)	
Adj	P	
(FDR)	
	
E2	
1.	neonatal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
2.	preweaning	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 -0.723	 0.293	 3139	 -2.47	 0.0137	 0.21	 *0.027	 *0.027	 *0.027	 M>F	
4.	adult	 0.0942	 0.249	 3139	 0.38	 0.705	 0.99	 0.71	 0.71	 0.71	 	
P4	
1.	neonatal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
2.	preweaning	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 0.170	 0.317	 3326	 0.54	 0.591	 0.99	 0.59	 0.59	 0.59	 	
4.	adult	 0.863	 0.262	 3326	 3.30	 0.0010	 *0.027	 *0.002	 *0.002	 *0.002	 F>M	
T	
1.	neonatal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
2.	preweaning	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 -1.94	 0.212	 2982	 -9.17	 <0.0001	 *<0.0001	 *<0.0001	 *<0.0001	 *<0.0001	 M>F	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	p-value	adjusted	by	method	in	parentheses	(“Tukey”	=	Tukey	HSD,	“Holm”	=	step-down	Holm,	“Hoch”	=	step-up	Hochberg,	“FDR”	
=	False	discovery	rate),	alpha	=	0.05.	
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Table	6.		Sex	Effect:		Differences	of	AGE_CAT(STRAIN*SEX)	LSMs	(Female	vs.	Male)		
	
	 Age	 Strain	 Estimate	 SE	 DF	 t	Value	 Pr	>	|t|	(Raw)	
Adj	P	
(Tukey)	
Adj	P	
(Holm)	
Adj	P	
(Hoch)	
Adj	P	
(FDR)	
	
E2	
1.	neonatal	 SD	 -0.589	 0.992	 3139	 -0.59	 0.55	 1	 1	 0.92	 0.69	 	Wistar	 -1.92	 0.634	 3139	 -3.03	 0.0025	 0.23	 *0.023	 *0.023	 *0.013	 M>F	
2.	preweaning	 SD	 -0.764	 1.012	 3139	 -0.75	 0.45	 1	 1	 0.92	 0.69	 	Wistar	 -1.44	 0.627	 3139	 -2.3	 0.022	 0.75	 0.151	 0.15	 0.054	 	
3.	prepubertal	
LE	 -0.0243	 0.232	 3139	 -0.1	 0.92	 1	 1	 0.92	 0.92	 	
SD	 -1.35	 0.533	 3139	 -2.53	 0.011	 0.58	 0.090	 0.090	 *0.038	 M>F	
Wistar	 -0.796	 0.624	 3139	 -1.28	 0.20	 0.99	 1	 0.92	 0.41	 	
4.	adult	
LE	 0.511	 0.160	 3139	 3.19	 0.0014	 0.16	 *0.014	 *0.014	 *0.013	 F>M	
SD	 -0.326	 0.489	 3139	 -0.67	 0.51	 1	 1	 0.92	 0.69	 	
Wistar	 0.0972	 0.497	 3139	 0.2	 0.85	 1	 1	 0.92	 0.92	 	
P4	
1.	neonatal	 SD	 0.972	 0.454	 3326	 2.14	 0.033	 0.88	 0.293	 0.29	 0.14	 	Wistar	 -0.148	 0.700	 3326	 -0.21	 0.83	 1	 1	 0.83	 0.83	 	
2.	preweaning	 SD	 0.609	 0.451	 3326	 1.35	 0.18	 0.99	 1	 0.83	 0.36	 	Wistar	 -0.232	 0.551	 3326	 -0.42	 0.67	 1	 1	 0.83	 0.83	 	
3.	prepubertal	
LE	 0.233	 0.275	 3326	 0.8ƒ5	 0.40	 1	 1	 0.83	 0.66	 	
SD	 0.434	 0.607	 3326	 0.72	 0.47	 1	 1	 0.83	 0.68	 	
Wistar	 -0.156	 0.547	 3326	 -0.28	 0.78	 1	 1	 0.83	 0.83	 	
4.	adult	
LE	 0.368	 0.180	 3326	 2.05	 0.041	 0.92	 0.327	 0.33	 0.14	 	
SD	 1.63	 0.487	 3326	 3.34	 0.0008	 0.11	 *0.008	 *0.008	 *0.008	 F>M	
Wistar	 0.595	 0.438	 3326	 1.36	 0.17	 0.99	 1	 0.83	 0.36	 	
T	
1.	neonatal	 SD	 -1.52	 0.385	 2982	 -3.95	 <0.0001	 *0.01	 *0.001	 *<0.0001	 *<0.0001	 M>F	
2.	preweaning	 SD	 -0.891	 0.426	 2982	 -2.09	 0.037	 0.82	 0.067	 *0.037	 *0.037	 M>F	
3.	prepubertal	 LE	 -2.81	 0.364	 2982	 -7.72	 <0.0001	 *<0.0001	 *0.001	 *<0.0001	 *<0.0001	 M>F	SD	 -0.892	 0.420	 2982	 -2.12	 0.033	 0.80	 0.067	 *0.037	 *0.037	 M>F	
4.	adult	
LE	 -1.33	 0.134	 2982	 -9.98	 <0.0001	 *<0.0001	 *<0.0001	 *<0.0001	 *<0.0001	 M>F	
SD	 -2.16	 0.357	 2982	 -6.05	 <0.0001	 *<0.0001	 *<0.0001	 *<0.0001	 *<0.0001	 M>F	
Wistar	 -2.32	 0.500	 2982	 -4.65	 <0.0001	 *0.0005	 *<0.0001	 *<0.0001	 *<0.0001	 M>F	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	p-value	adjusted	by	method	in	parentheses	(“Tukey”	=	Tukey	HSD,	“Holm”	=	step-down	Holm,	“Hoch”	=	step-up	Hochberg,	“FDR”	
=	False	discovery	rate),	alpha	=	0.05.	
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Table	7.		Age	Effect:		Differences	of	AGE_CAT	LSMs	
	
	 AGE_CAT	 AGE_CAT	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	 Adj	P	 	
E2	
1.	neonatal	
2.	preweaning	 -0.4259	 0.1109	 3139	 -3.84	 0.0001	 *0.0007	 2>1	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
2.	preweaning	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
3.	prepubertal	 4.	adult	 1.0837	 0.1145	 3139	 9.47	 <.0001	 *<.0001	 3>4	5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
P4	
1.	neonatal	
2.	preweaning	 -0.4825	 0.1824	 3326	 -2.65	 0.0082	 *0.0409	 2>1	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
2.	preweaning	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
3.	prepubertal	 4.	adult	 -0.4112	 0.3959	 3326	 -1.04	 0.2991	 0.7268	 	5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
T	
1.	neonatal	
2.	preweaning	 Non-est	 .	 .	 .	 .	 .	 	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
2.	preweaning	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
3.	prepubertal	 4.	adult	 Non-est	 .	 .	 .	 .	 .	 	5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	Tukey-adjusted	p-value,	“Adj	P,”	alpha	=	0.05.			 	
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Table	8.		Age	Effect:		Differences	of	AGE_CAT(SEX)	LSMs	
	
	 SEX	 AGE_CAT	 AGE_CAT	 Estimate	 SE	 DF	 t	Value	 Pr	>	|t|	 Adj	P	(Tukey)	
Adj	P	
(Holm)	
Adj	P	
(Hoch)	
Adj	P	
(FDR)	
	
E2	
F	
1.	neonatal	
2.	preweaning	 -0.5015	 0.08079	 3139	 -6.21	 <.0001	 *<.0001	 *0.0004	 *0.0002	 *0.00013	 2>1	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
2.	preweaning	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 4.	adult	 0.6750	 0.1140	 3139	 5.92	 <.0001	 *<.0001	 *0.0004	 *0.0002	 *0.00013	 3>4	5.	aging	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
M	
1.	neonatal	
2.	preweaning	 -0.3504	 0.2066	 3139	 -1.70	 0.0901	 0.6902	 0.0901	 0.0901	 0.0901	 	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
2.	preweaning	 3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 4.	adult	 1.4925	 0.1734	 3139	 8.61	 <.0001	 *<.0001	 *0.0004	 *0.0002	 *0.00013	 3>4	
P4	
F	
1.	neonatal	 2.	preweaning	 -0.3709	 0.1471	 3326	 -2.52	 0.0117	 0.2219	 0.0702	 0.0702	 0.0558	 	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
2.	preweaning	 3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 4.	adult	 -0.7577	 0.3927	 3326	 -1.93	 0.0538	 0.5933	 0.2152	 0.2152	 0.1076	 	
5.	aging	 -0.5050	 0.4068	 3326	 -1.24	 0.2146	 0.9473	 0.4292	 0.4292	 0.25752	 	
4.	adult	 5.	aging	 0.2527	 0.1073	 3326	 2.36	 0.0186	 0.3095	 0.093	 0.093	 0.0558	 	
M	
1.	neonatal	 2.	preweaning	 -0.5942	 0.3339	 3326	 -1.78	 0.0752	 0.6959	 0.2256	 0.2256	 0.1128	 	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
2.	preweaning	 3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 4.	adult	 -0.06463	 0.4266	 3326	 -0.15	 0.8796	 1	 0.8796	 0.8796	 0.8796	 	
T	
F	
1.	neonatal	 2.	preweaning	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
M	
1.	neonatal	 2.	preweaning	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
2.	preweaning	 3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
3.	prepubertal	 4.	adult	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	p-value	adjusted	by	method	in	parentheses	(“Tukey”	=	Tukey	HSD,	“Holm”	=	step-down	Holm,	“Hoch”	=	step-up	Hochberg,	“FDR”	
=	False	discovery	rate),	alpha	=	0.05.		
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Table	9.		Age	Effect:		Differences	of	AGE_CAT(STRAIN)	LSMs	
	
	 Age	 Age	 Strain	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	 Adj	P	
E2	
1.	neonatal	
2.	preweaning	 SD	 -0.5312	 0.1197	 3139	 -4.44	 <.0001	 *0.0004	W	 -0.3207	 0.1868	 3139	 -1.72	 0.0861	 0.7862	
3.	prepubertal	 SD	 -0.4436	 0.5506	 3139	 -0.81	 0.4205	 0.9985	W	 -0.1571	 0.1838	 3139	 -0.85	 0.3929	 0.9976	
4.	adult	 SD	 0.5910	 0.5421	 3139	 1.09	 0.2757	 0.9857	 	W	 0.3775	 0.2118	 3139	 1.78	 0.0748	 0.7465	
2.	preweaning	
3.	prepubertal	 SD	 0.08765	 0.5590	 3139	 0.16	 0.8754	 1	W	 0.1635	 0.1783	 3139	 0.92	 0.3591	 0.9960	
4.	adult	 SD	 1.1223	 0.5510	 3139	 2.04	 0.0418	 0.5729	W	 0.6981	 0.2066	 3139	 3.38	 0.0007	 *0.0255	
3.	prepubertal	
4.	adult	
LE	 1.6820	 0.2484	 3139	 6.77	 <.0001	 *<.0001	
SD	 1.0346	 0.1200	 3139	 8.62	 <.0001	 *<.0001	
Wistar	 0.5346	 0.2038	 3139	 2.62	 0.0087	 0.2068	
5.	aging	 LE	 Non-est	 .	 .	 .	 .	 .	
4.	adult	 5.	aging	 LE	 Non-est	 .	 .	 .	 .	 .	
P4	
1.	neonatal	
2.	preweaning	 SD	 -0.5525	 0.1574	 3326	 -3.51	 0.0005	 *0.0165	Wistar	 -0.4125	 0.3286	 3326	 -1.26	 0.2094	 0.9630	
3.	prepubertal	 SD	 -1.2679	 0.2784	 3326	 -4.55	 <.0001	 *0.0002	Wistar	 -0.6311	 0.3050	 3326	 -2.07	 0.0386	 0.5493	
4.	adult	 SD	 -1.3353	 0.2170	 3326	 -6.15	 <.0001	 *<.0001	Wistar	 -1.4331	 0.2844	 3326	 -5.04	 <.0001	 *<.0001	
5.	aging	 SD	 Non-est	 .	 .	 .	 .	 .	Wistar	 Non-est	 .	 .	 .	 .	 .	
2.	preweaning	
3.	prepubertal	 SD	 -0.7154	 0.2514	 3326	 -2.85	 0.0045	 0.1219	Wistar	 -0.2186	 0.2428	 3326	 -0.90	 0.3679	 0.9965	
4.	adult	 SD	 -0.7828	 0.1835	 3326	 -4.27	 <.0001	 *0.0009	Wistar	 -1.0206	 0.1962	 3326	 -5.20	 <.0001	 *<.0001	
5.	aging	 SD	 Non-est	 .	 .	 .	 .	 .	Wistar	 Non-est	 .	 .	 .	 .	 .	
3.	prepubertal	
4.	adult	
LE	 -0.3641	 1.1554	 3326	 -0.32	 0.7527	 1	
SD	 -0.06740	 0.2013	 3326	 -0.33	 0.7377	 1	
Wistar	 -0.8020	 0.1872	 3326	 -4.28	 <.0001	 *0.0008	
5.	aging	
LE	 Non-est	 .	 .	 .	 .	 .	
SD	 Non-est	 .	 .	 .	 .	 .	
Wistar	 Non-est	 .	 .	 .	 .	 .	
4.	adult	 5.	aging	
LE	 Non-est	 .	 .	 .	 .	 .	
SD	 Non-est	 .	 .	 .	 .	 .	
Wistar	 Non-est	 .	 .	 .	 .	 .	
T	
1.	neonatal	
2.	preweaning	 SD	 -0.8610	 0.1091	 2982	 -7.89	 <.0001	 *<.0001	
3.	prepubertal	 LE	 Non-est	 .	 .	 .	 .	 .	SD	 -0.07693	 0.1399	 2982	 -0.55	 0.5826	 0.9981	
4.	adult	 LE	 Non-est	 .	 .	 .	 .	 .	SD	 -0.6139	 0.09694	 2982	 -6.33	 <.0001	 *<.0001	
5.	aging	 LE	 Non-est	 .	 .	 .	 .	 .	
2.	preweaning	
3.	prepubertal	 SD	 0.7841	 0.1651	 2982	 4.75	 <.0001	 *<.0001	Wistar	 Non-est	 .	 .	 .	 .	 .	
4.	adult	 SD	 0.2471	 0.1329	 2982	 1.86	 0.0630	 0.5073	Wistar	 Non-est	 .	 .	 .	 .	 .	
3.	prepubertal	
4.	adult	
LE	 -1.3169	 0.1937	 2982	 -6.80	 <.0001	 *<.0001	
SD	 -0.5370	 0.1253	 2982	 -4.29	 <.0001	 *0.0004	
Wistar	 Non-est	 .	 .	 .	 .	 .	
5.	aging	 LE	 Non-est	 .	 .	 .	 .	 .	
4.	adult	 5.	aging	 LE	 Non-est	 .	 .	 .	 .	 .		Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	Tukey-adjusted	p-value,	“Adj	P,”	alpha	=	0.05.	
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Table	10.		Age	Effect:		Differences	of	AGE_CAT(STRAIN*SEX)	LSMs	
	
	 SEX	 AGE_CAT	 AGE_CAT	 STRAIN	 Estimate	 SE	 DF	 t	Value	 Pr	>	|t|	 Adj	P	(Tukey)	
Adj	P	
(Holm)	
Adj	P	
(Hoch)	
Adj	P		
(FDR)	
	
E2	
F	
1.	neonat	
2.	prewean	 SD	 -0.444	 0.102	 3139	 -4.34	 <.0001	 *0.0027	 *0.0028	 *0.0018	 *0.0003	 2>1	Wistar	 -0.560	 0.125	 3139	 -4.47	 <.0001	 *0.0015	 *0.0028	 *0.0018	 *0.0003	 2>1	
3.	prepub	 SD	 -0.0630	 0.0910	 3139	 -0.69	 0.49	 1	 1	 0.85	 0.58	 	Wistar	 -0.719	 0.131	 3139	 -5.5	 <.0001	 *<.0001	 *0.0028	 *0.0018	 *0.0003	 3>1	
4.	adult	 SD	 0.459	 0.105	 3139	 4.36	 <.0001	 *0.0024	 *0.0028	 *0.0018	 *0.0003	 1>4	Wistar	 -0.631	 0.118	 3139	 -5.36	 <.0001	 *<.0001	 *0.0028	 *0.0018	 *0.0003	 4>1	
2.	prewean	
3.	prepub	 SD	 0.381	 0.104	 3139	 3.67	 0.0002	 *0.036	 *0.0034	 *0.0032	 *0.0004	 2>3	Wistar	 -0.160	 0.128	 3139	 -1.25	 0.21	 1	 1	 0.85	 0.33	 	
4.	adult	 SD	 0.903	 0.125	 3139	 7.26	 <.0001	 *<.0001	 *0.0028	 *0.0018	 *0.0003	 2>4	Wistar	 -0.0717	 0.112	 3139	 -0.64	 0.52	 1	 1	 0.85	 0.58	 	
3.	prepub	
4.	adult	
LE	 1.41	 0.301	 3139	 4.7	 <.0001	 *0.0005	 *0.0028	 *0.0018	 *0.0003	 3>4	
SD	 0.522	 0.109	 3139	 4.77	 <.0001	 *0.0004	 *0.0028	 *0.0018	 *0.0003	 3>4	
Wistar	 0.0881	 0.117	 3139	 0.75	 0.45	 1	 1	 0.85	 0.58	 	
5.	aging	 LE	 1.50	 0.392	 3139	 3.81	 0.0001	 *0.022	 *0.0028	 *0.0018	 *0.0003	 3>5	
4.	adult	 5.	aging	 LE	 0.0812	 0.252	 3139	 0.32	 0.75	 1	 1	 0.85	 0.81	 	
M	
1.	neonat	
2.	prewean	 SD	 -0.619	 0.217	 3139	 -2.86	 0.0043	 0.34	 0.060	 0.060	 *0.0080	 2>1	Wistar	 -0.0820	 0.352	 3139	 -0.23	 0.82	 1	 1	 0.85	 0.85	 	
3.	prepub	 SD	 -0.824	 1.10	 3139	 -0.75	 0.45	 1	 1	 0.85	 0.58	 	Wistar	 0.405	 0.344	 3139	 1.18	 0.24	 1	 1	 0.85	 0.33	 	
4.	adult	 SD	 0.723	 1.08	 3139	 0.67	 0.50	 1	 1	 0.85	 0.58	 	Wistar	 1.39	 0.407	 3139	 3.41	 0.0007	 0.084	 *0.011	 *0.011	 *0.0014	 1>4	
2.	prewean	
3.	prepub	 SD	 -0.205	 1.11	 3139	 -0.18	 0.85	 1	 1	 0.85	 0.85	 	Wistar	 0.487	 0.333	 3139	 1.46	 0.14	 1	 1	 0.85	 0.24	 	
4.	adult	 SD	 1.34	 1.10	 3139	 1.23	 0.22	 1	 1	 0.85	 0.33	 	Wistar	 1.47	 0.398	 3139	 3.69	 0.0002	 *0.034	 *0.0034	 *0.0032	 *0.0004	 2>4	
3.	prepub	 4.	adult	
LE	 1.95	 0.269	 3139	 7.24	 <.0001	 *<.0001	 *0.0028	 *0.0018	 *0.0003	 3>4	
SD	 1.55	 0.214	 3139	 7.24	 <.0001	 *<.0001	 *0.0028	 *0.0018	 *0.0003	 3>4	
Wistar	 0.981	 0.390	 3139	 2.51	 0.012	 0.60	 0.16	 0.16	 *0.021	 3>4	
P4	
F	
1.	neonat	
2.	prewean	 SD	 -0.371	 0.131	 3326	 -2.83	 0.0047	 0.39	 0.099	 0.099	 *0.011	 2>1	Wistar	 -0.371	 0.263	 3326	 -1.41	 0.16	 1	 1	 0.81	 0.24	 	
3.	prepub	 SD	 -0.999	 0.141	 3326	 -7.09	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 3>1	Wistar	 -0.627	 0.296	 3326	 -2.12	 0.034	 0.90	 0.62	 0.5600	 0.060	 	
4.	adult	 SD	 -1.66	 0.125	 3326	 -13.34	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 4>1	Wistar	 -1.80	 0.265	 3326	 -6.81	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 4>1	
5.	aging	 SD	 -1.53	 0.254	 3326	 -6.04	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 5>1	Wistar	 -1.89	 0.349	 3326	 -5.41	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 5>1	
2.	prewean	
3.	prepub	 SD	 -0.628	 0.137	 3326	 -4.59	 <.0001	 *0.0011	 *0.0036	 *0.0023	 *0.0003	 3>2	Wistar	 -0.257	 0.214	 3326	 -1.2	 0.23	 1	 1	 0.81	 0.30	 	
4.	adult	 SD	 -1.29	 0.123	 3326	 -10.49	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 4>2	Wistar	 -1.43	 0.175	 3326	 -8.18	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 4>2	
5.	aging	 SD	 -1.16	 0.253	 3326	 -4.59	 <.0001	 *0.001	 *0.0036	 *0.0023	 *0.0003	 5>2	Wistar	 -1.52	 0.286	 3326	 -5.3	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 5>2	
3.	prepub	
4.	adult	
LE	 -0.432	 1.16	 3326	 -0.37	 0.71	 1	 1	 0.81	 0.76	 	
SD	 -0.664	 0.124	 3326	 -5.36	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 4>3	
Wistar	 -1.18	 0.195	 3326	 -6.04	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 4>3	
5.	aging	
LE	 0.279	 1.16	 3326	 0.24	 0.81	 1	 1	 0.81	 0.81	 	
SD	 -0.534	 0.253	 3326	 -2.11	 0.035	 0.8988	 0.62	 0.56	 0.060	 	
Wistar	 -1.26	 0.299	 3326	 -4.22	 <.0001	 *0.0053	 *0.0036	 *0.0023	 *0.0003	 5>3	
4.	adult	 5.	aging	
LE	 0.710	 0.0579	 3326	 12.26	 <.0001	 *<.0001	 *0.0036	 *0.0023	 *0.0003	 4>5	
SD	 0.13	 0.222	 3326	 0.59	 0.56	 1	 1	 0.81	 0.65	 	
Wistar	 -0.0824	 0.227	 3326	 -0.36	 0.72	 1	 1	 0.81	 0.76	 	
M	
1.	neonat	
2.	prewean	 SD	 -0.734	 0.286	 3326	 -2.56	 0.010	 0.61	 0.21	 0.21	 *0.022	 2>1	Wistar	 -0.455	 0.602	 3326	 -0.75	 0.45	 1	 1	 0.81	 0.54	 	
3.	prepub	 SD	 -1.54	 0.539	 3326	 -2.85	 0.0044	 0.38	 0.097	 0.097	 *0.011	 3>1	Wistar	 -0.635	 0.533	 3326	 -1.19	 0.23	 1	 1	 0.81	 0.30	 	
4.	adult	 SD	 -1.01	 0.416	 3326	 -2.42	 0.015	 0.71	 0.29	 0.29	 *0.031	 4>1	Wistar	 -1.06	 0.503	 3326	 -2.11	 0.035	 0.90	 0.62	 0.56	 0.060	 	
2.	prewean	
3.	prepub	 SD	 -0.803	 0.484	 3326	 -1.66	 0.097	 0.99	 1	 0.81	 0.15	 	Wistar	 -0.181	 0.436	 3326	 -0.41	 0.68	 1	 1	 0.81	 0.76	 	
4.	adult	 SD	 -0.274	 0.346	 3326	 -0.79	 0.43	 1	 1	 0.81	 0.53	 	Wistar	 -0.607	 0.351	 3326	 -1.73	 0.084	 0.99	 1	 0.81	 0.14	 	
3.	prepub	 4.	adult	
LE	 -0.297	 1.18	 3326	 -0.25	 0.80	 1	 1	 0.81	 0.81	 	
SD	 0.529	 0.383	 3326	 1.38	 0.17	 1	 1	 0.81	 0.24	 	
Wistar	 -0.426	 0.320	 3326	 -1.33	 0.18	 1	 1	 0.81	 0.25	 	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	p-value	adjusted	by	method	in	parentheses	(“Tukey”	=	Tukey	HSD,	“Holm”	=	step-down	Holm,	“Hoch”	=	step-up	Hochberg,	“FDR”	
=	False	discovery	rate),	alpha	=	0.05.	
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Table	10	(continued).	Age	Effect:		Differences	of	AGE_CAT(STRAIN*SEX)	LSMs	
	
T	
F	
1.	neonat	
2.	prewean	 SD	 -1.18	 0.0861	 2982	 -13.65	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 2>1	
3.	prepub	 SD	 -0.391	 0.0955	 2982	 -4.1	 <.0001	 *0.0056	 *0.0056	 *0.0021	 *0.0009	 3>1	
4.	adult	 SD	 -0.293	 0.114	 2982	 -2.58	 0.01	 0.47	 0.47	 0.070	 0.070	 	
2.	prewean	
3.	prepub	 SD	 0.785	 0.101	 2982	 7.74	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 2>3	Wistar	 1.82	 0.199	 2982	 9.15	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 2>3	
4.	adult	 SD	 0.883	 0.12	 2982	 7.36	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 2>4	Wistar	 -0.141	 0.172	 2982	 -0.82	 0.41	 1	 1	 1	 0.45	 	
3.	prepub	
4.	adult	
LE	 -2.05	 0.373	 2982	 -5.51	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 4>3	
SD	 0.0985	 0.13	 2982	 0.76	 0.45	 1	 1	 1	 0.45	 	
Wistar	 -1.96	 0.172	 2982	 -11.4	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 4>3	
5.	aging	 LE	 -1.89	 0.431	 2982	 -4.38	 <.0001	 *0.0016	 *0.0016	 *0.0021	 *0.0009	 5>3	
4.	adult	 5.	aging	 LE	 0.165	 0.216	 2982	 0.76	 0.45	 1	 1	 1	 0.45	 	
M	
1.	neonat	
2.	prewean	 SD	 -0.547	 0.200	 2982	 -2.73	 0.0064	 0.36	 0.36	 0.051	 0.051	 	
3.	prepub	
LE	 -1.69	 0.358	 2982	 -4.74	 <.0001	 *0.0003	 *0.0003	 *0.0021	 *0.0009	 3>1	
SD	 0.237	 0.263	 2982	 0.9	 0.37	 1	 1	 1	 0.45	 	
4.	adult	
LE	 -2.28	 0.342	 2982	 -6.65	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 4>1	
SD	 -0.935	 0.157	 2982	 -5.95	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 4>1	
2.	prewean	
3.	prepub	 SD	 0.784	 0.314	 2982	 2.49	 0.013	 0.54	 0.54	 0.076	 0.076	 	
4.	adult	 SD	 -0.389	 0.237	 2982	 -1.64	 0.10	 0.98	 0.98	 0.51	 0.45	 	
3.	prepub	 4.	adult	 LE	 -0.580	 0.104	 2982	 -5.58	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 4>3	SD	 -1.17	 0.214	 2982	 -5.47	 <.0001	 *<.0001	 *<.0001	 *0.0021	 *0.0009	 4>3	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	p-value	adjusted	by	method	in	parentheses	(“Tukey”	=	Tukey	HSD,	“Holm”	=	step-down	Holm,	“Hoch”	=	step-up	Hochberg,	“FDR”	
=	False	discovery	rate),	alpha	=	0.05.	
	
Table	11.		Strain	Effect:		Differences	of	STRAIN	LSMs	
	
	 STRAIN	 STRAIN	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	 Adj	P	
E2	
SD	 Wistar	 0.177	 0.380	 3139	 0.47	 0.64	 0.64	
LE	 SD	 Non-est	 .	 .	 .	 .	 .	
LE	 Wistar	 Non-est	 .	 .	 .	 .	 .	
P4	
SD	 Wistar	 Non-est	 .	 .	 .	 .	 .	
LE	 SD	 Non-est	 .	 .	 .	 .	 .	
LE	 Wistar	 Non-est	 .	 .	 .	 .	 .	
T	
SD	 Wistar	 Non-est	 .	 .	 .	 .	 .	
LE	 SD	 Non-est	 .	 .	 .	 .	 .	
LE	 Wistar	 Non-est	 .	 .	 .	 .	 .	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	Tukey-adjusted	p-value,	“Adj	P,”	alpha	=	0.05.		
Table	12.		Strain	Effect:		Differences	of	STRAIN*SEX	LSMs	
	
	 SEX	 STRAIN	 STRAIN	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	 Adj	P	(Tukey)	
Adj	P	
(Holm)	
Adj	P	
(Hoch)	
Adj	P	
(FDR)	
	
E2	
F	
SD	 Wistar	 0.306	 0.131	 3139	 2.34	 0.019	 0.088	 *0.038	 *0.038	 *0.038	 SD>W	
LE	 SD	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
LE	 Wistar	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
M	
SD	 Wistar	 0.0484	 0.748	 3139	 0.06	 0.95	 1	 0.95	 0.95	 0.95	 	
LE	 SD	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
LE	 Wistar	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
P4	
F	 SD	 Wistar	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	LE	 SD	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
M	
LE	 Wistar	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
SD	 Wistar	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
LE	 SD	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
T	
F	
SD	 Wistar	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
LE	 SD	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
LE	 Wistar	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
M	
SD	 Wistar	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
LE	 SD	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
LE	 Wistar	 Non-est	 .	 .	 .	 .	 .	 	 	 	 	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	p-value	adjusted	by	method	in	parentheses	(“Tukey”	=	Tukey	HSD,	“Holm”	=	step-down	Holm,	“Hoch”	=	step-up	Hochberg,	“FDR”	
=	False	discovery	rate),	alpha	=	0.05.	
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Table	13.		Strain	Effect:		Differences	of	AGE_CAT(STRAIN)	LSMs	
	
	 STRAIN	 STRAIN	 AGE_CAT	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	 Adj	P	 	
E2	
SD	 Wistar	
1.	neonatal	 0.107	 0.578	 3139	 0.18	 0.85	 1	 	
2.	preweaning	 0.317	 0.585	 3139	 0.54	 0.59	 1	 	
3.	prepubertal	 0.393	 0.396	 3139	 0.99	 0.32	 0.99	 	
4.	adult	 -0.107	 0.334	 3139	 -0.32	 0.75	 1	 	
LE	 SD	 3.	prepubertal	 -0.342	 0.407	 3139	 -0.84	 0.40	 1	 	4.	adult	 -0.990	 0.311	 3139	 -3.18	 0.0015	 0.048	 SD>LE	
LE	 Wistar	 3.	prepubertal	 0.0513	 0.442	 3139	 0.12	 0.91	 1	 	4.	adult	 -1.10	 0.323	 3139	 -3.40	 0.0007	 0.024	 	
P4	
SD	 Wistar	
1.	neonatal	 -0.147	 0.359	 3326	 -0.41	 0.68	 1	 	
2.	preweaning	 -0.00721	 0.270	 3326	 -0.03	 0.98	 1	 	
3.	prepubertal	 0.490	 0.355	 3326	 1.38	 0.17	 0.93	 	
4.	adult	 -0.245	 0.261	 3326	 -0.94	 0.35	 1	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
LE	 SD	
3.	prepubertal	 0.0690	 1.15	 3326	 0.06	 0.95	 1	 	
4.	adult	 0.366	 0.415	 3326	 0.88	 0.38	 1	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
LE	 Wistar	
3.	prepubertal	 0.559	 1.14	 3326	 0.49	 0.62	 1	 	
4.	adult	 0.121	 0.399	 3326	 0.30	 0.76	 1	 	
5.	aging	 Non-est	 .	 .	 .	 .	 .	 	
T	
SD	 Wistar	
2.	preweaning	 Non-est	 .	 .	 .	 .	 .	 	
3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	
4.	adult	 -0.715	 0.306	 2982	 -2.33	 0.020	 0.23	 	
LE	 SD	
1.	neonatal	 Non-est	 .	 .	 .	 .	 .	 	
3.	prepubertal	 -0.161	 0.316	 2982	 -0.51	 0.61	 1	 	
4.	adult	 0.619	 0.247	 2982	 2.50	 0.012	 0.16	 	
LE	 Wistar	 3.	prepubertal	 Non-est	 .	 .	 .	 .	 .	 	4.	adult	 -0.0959	 0.308	 2982	 -0.31	 0.76	 1	 	
Separate	analyses	run	by	hormone.	
*statistically	significant	according	to	Tukey-adjusted	p-value,	“Adj	P,”	alpha	=	0.05.		
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Table	14.		Strain	Effect:		Differences	of	AGE_CAT(STRAIN*SEX)	LSMs	
	
	 SEX	 STRAIN	 STRAIN	 AGE_CAT	 Estimate	 SE	 DF	 t	Value	 Pr	>	|t|	 Adj	P	(Tukey)	
Adj	P	
(Holm)	
Adj	P	
(Hoch)	
Adj	P	
(FDR)	
	
E2	
F	
SD	 Wistar	
1.	neonatal	 0.772	 0.155	 3139	 4.98	 <.0001	 *<.0001	 *0.0016	 *0.0016	 *0.0016	 SD>W	
2.	preweaning	 0.656	 0.180	 3139	 3.64	 0.0003	 *0.040	 *0.0042	 *0.0042	 *0.0016	 SD>W	
3.	prepubertal	 0.116	 0.177	 3139	 0.65	 0.51	 1	 1	 0.98	 0.68	 	
4.	adult	 -0.318	 0.140	 3139	 -2.27	 0.023	 0.78	 0.23	 0.23	 0.053	 	
LE	 SD	 3.	prepubertal	 0.321	 0.356	 3139	 0.9	 0.37	 1	 1	 0.98	 0.56	 	4.	adult	 -0.571	 0.209	 3139	 -2.73	 0.0063	 0.43	 0.082	 0.082	 *0.025	 SD>LE	
LE	 Wistar	 3.	prepubertal	 0.437	 0.379	 3139	 1.15	 0.25	 1	 1	 0.98	 0.44	 	4.	adult	 -0.889	 0.241	 3139	 -3.69	 0.0002	 *0.034	 *0.0030	 *0.0030	 *0.0016	 W>LE	
M	
SD	 Wistar	
1.	neonatal	 -0.559	 1.14	 3139	 -0.49	 0.63	 1	 1	 0.98	 0.71	 	
2.	preweaning	 -0.0221	 1.16	 3139	 -0.02	 0.98	 1	 1	 0.98	 0.98	 	
3.	prepubertal	 0.670	 0.772	 3139	 0.87	 0.39	 1	 1	 0.98	 0.56	 	
4.	adult	 0.104	 0.653	 3139	 0.16	 0.87	 1	 1	 0.98	 0.93	 	
LE	 SD	 3.	prepubertal	 -1.00	 0.612	 3139	 -1.64	 0.10	 0.99	 0.90	 0.90	 0.20	 	4.	adult	 -1.41	 0.530	 3139	 -2.66	 0.0079	 0.48	 0.095	 0.09	 *0.025	 SD>LE	
LE	 Wistar	 3.	prepubertal	 -0.334	 0.685	 3139	 -0.49	 0.63	 1	 1	 0.98	 0.71	 	4.	adult	 -1.30	 0.535	 3139	 -2.44	 0.015	 0.66	 0.16	 0.16	 *0.040	 W>LE	
P4	
F	
SD	 Wistar	
1.	neonatal	 0.413	 0.441	 3326	 0.94	 0.35	 1	 1	 0.99	 0.74	 	
2.	preweaning	 0.413	 0.394	 3326	 1.05	 0.29	 1	 1	 0.99	 0.70	 	
3.	prepubertal	 0.785	 0.401	 3326	 1.96	 0.051	 0.95	 0.96	 0.96	 0.34	 	
4.	adult	 0.271	 0.338	 3326	 0.8	 0.42	 1	 1	 0.99	 0.80	 	
5.	aging	 0.0586	 0.443	 3326	 0.13	 0.89	 1	 1	 0.99	 0.99	 	
LE	 SD	
3.	prepubertal	 -0.0318	 1.14	 3326	 -0.03	 0.98	 1	 1	 0.99	 0.99	 	
4.	adult	 -0.264	 0.405	 3326	 -0.65	 0.51	 1	 1	 0.99	 0.82	 	
5.	aging	 -0.845	 0.455	 3326	 -1.86	 0.064	 0.97	 1	 0.99	 0.34	 	
LE	 Wistar	
3.	prepubertal	 0.753	 1.16	 3326	 0.65	 0.51	 1	 1	 0.99	 0.82	 	
4.	adult	 0.00687	 0.413	 3326	 0.02	 0.99	 1	 1	 0.99	 0.99	 	
5.	aging	 -0.786	 0.465	 3326	 -1.69	 0.091	 1	 1	 0.99	 0.34	 	
M	
SD	 Wistar	
1.	neonatal	 -0.707	 0.566	 3326	 -1.25	 0.21	 1	 1	 0.99	 0.67	 	
2.	preweaning	 -0.428	 0.371	 3326	 -1.15	 0.25	 1	 1	 0.99	 0.67	 	
3.	prepubertal	 0.195	 0.588	 3326	 0.33	 0.74	 1	 1	 0.99	 0.97	 	
4.	adult	 -0.761	 0.399	 3326	 -1.91	 0.057	 0.96	 1	 0.99	 0.34	 	
LE	 SD	 3.	prepubertal	 0.170	 1.25	 3326	 0.14	 0.89	 1	 1	 0.99	 0.99	 	4.	adult	 0.996	 0.561	 3326	 1.77	 0.076	 0.98	 1	 0.99	 0.34	 	
LE	 Wistar	 3.	prepubertal	 0.364	 1.21	 3326	 0.3	 0.76	 1	 1	 0.99	 0.97	 	4.	adult	 0.235	 0.509	 3326	 0.46	 0.64	 1	 1	 0.99	 0.94	 	
T	
F	
SD	 Wistar	
2.	preweaning	 0.390	 0.588	 2982	 0.66	 0.51	 1	 1	 0.62	 0.55	 	
3.	prepubertal	 1.42	 0.589	 2982	 2.41	 0.016	 0.60	 0.13	 0.13	 *0.038	 SD>W	
4.	adult	 -0.634	 0.561	 2982	 -1.13	 0.26	 1	 1	 0.62	 0.39	 	
LE	 SD	 3.	prepubertal	 -1.12	 0.501	 2982	 -2.23	 0.026	 0.73	 0.15	 0.15	 *0.044	 SD>LE	4.	adult	 1.034	 0.382	 2982	 2.71	 0.0068	 0.38	 0.075	 0.075	 *0.032	 LE>SD	
LE	 Wistar	 3.	prepubertal	 0.303	 0.618	 2982	 0.49	 0.62	 1	 1	 0.62	 0.62	 	4.	adult	 0.400	 0.508	 2982	 0.79	 0.43	 1	 1	 0.62	 0.52	 	
M	
SD	 Wistar	 4.	adult	 -0.796	 0.242	 2982	 -3.29	 0.001	 0.092	 *0.012	 *0.012	 *0.012	 W>SD	
LE	 SD	
1.	neonatal	 -1.14	 0.428	 2982	 -2.65	 0.008	 0.41	 0.080	 0.080	 *0.032	 SD>LE	
3.	prepubertal	 0.796	 0.320	 2982	 2.49	 0.013	 0.54	 0.12	 0.12	 *0.038	 LE>SD	
4.	adult	 0.204	 0.221	 2982	 0.92	 0.36	 1	 1	 0.62	 0.48	 	
LE	 Wistar	 4.	adult	 -0.592	 0.257	 2982	 -2.31	 0.021	 0.68	 0.15	 0.15	 *0.042	 W>LE	
Separate	analyses	run	by	hormone.	
*statistically	 significant	according	 to	p-value	adjusted	by	method	 in	parentheses	 (“Tukey”	=	Tukey	HSD,	“Holm”	=	step-down	Holm,	“Hoch”	=	step-up	Hochberg,	
“FDR”	=	False	discovery	rate),	alpha	=	0.05.	
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Chapter	2:		Effect	of	Perinatal	Exposure	to	Bisphenol-A	on	Sex	Hormone	Levels	in	Young	Rats		
Introduction	
BPA	 (bisphenol	A)	 is	a	chemical	 compound	with	known	weak	estrogenic	activity	 that	 is	
commonly	used	as	an	additive	in	polycarbonate	plastic	products	 in	a	wide	variety	of	consumer	
products.	In	2006,	an	expert	panel	met	in	Chapel	Hill,	NC,	USA,	to	discuss	the	current	consensus	
and	gaps	in	knowledge	surrounding	the	effects	of	BPA	(vom	Saal,	et	al.,	2007).	They	reaffirmed	
that	both	the	pharmacokinetics	of	BPA	and	the	sensitivity	of	the	body	to	endocrine	disruptors	
vary	with	life	stage,	with	some	time-points	comprising	important	developmental	windows.	Due	
to	 life	stage	discrepancies	among	studies,	they	concluded,	that	further	 longitudinal	studies	are	
needed	to	properly	evaluate	the	comprehensive	effects	of	BPA	exposure	during	development	on	
the	reproductive	and	other	systems	throughout	the	organism’s	lifespan.	Their	conclusions	were	
updated	by	Vandenberg,	et	al.,	 (2013),	who	concluded	that	reproducible	effects	 in	animals	are	
produced	at	doses	0.1	to	0.0001	lower	than	the	current	LOAEL	of	50	mg/kg/day.	Heindel	(2005)	
pointed	out	that	any	particular	toxicant,	depending	on	the	time	or	duration	of	exposure,	has	the	
potential	 to	 exhibit	 a	 period	 of	 latency	 for	 any	 amount	 of	 time	 before	 effects	 are	 able	 to	 be	
observed,	with	the	onset	of	these	effects	potentially	occurring	as	early	as	the	neonatal	period	or	
as	late	as	adulthood.	
	 Numerous	 studies	 have	 demonstrated	 unfavorable	 effects	 of	 developmental	 BPA	
exposure	 at	 environmentally	 relevant	 dosages	 (“relevant-dose”)	 on	 adult	 reproductive	
parameters.	 Contrastingly,	 few	 studies	 have	 evaluated	 effects	 at	 other	 time	 points,	 including	
infantile	development,	which	spans	 from	parturition	 to	PND	10	 in	 the	 rat.	The	Developmental	
Origin	 of	 Health	 and	 Disease	 (DOHaD)	 theory	 is	 that	 exposure	 to	 environmental	 challenges	
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during	 early	 periods	 of	 development,	 during	 which	 tissue	 usually	 possess	 a	 higher	 degree	 of	
plasticity,	 can	 influence	 the	 risk	 of	 diseases	 later	 in	 life	 (Wadhwa,	 et	 al.,	 2009).	 Exposure	 to	
endocrine	 disruptors	 during	 childhood	 is	 of	 special	 concern	 because	 of	 the	 effects	 that	
hormonally-active	 substances	 can	 have	 on	 neurologic,	 endocrine,	 and	 reproductive	
development	(Diamanti-Kandarakis,	et	al.,	2009).		
Newborn	rats	are	less	developmentally	mature	than	humans.	Thus,	post-natal	day	(PND)	
10	 rats	 are	 used	 for	 comparison	 to	 human	 infants	 at	 birth	 (Clancy	 2007,	 Dobbing	 and	 Sands	
1979,	 Andrews	 and	 Fitzgerald	 1997).	 PND	 10	 is	 also	 a	 critical	 time	 for	 neuroendocrine	 and	
reproductive	development	 in	 rats,	 as	 the	hypothalamus	and	pituitary	are	 comparatively	much	
more	sensitive	to	sex	hormones	at	this	age	(Andrews,	et	al.,	1981).	Thus,	potentially	significant	
pathological	 effects	 could	 result	 from	 even	 small	 changes	 during	 that	 period.	 Here,	 we	
investigated	the	effect	of	orally	administered	BPA	during	the	perinatal	period	on	sex	hormones	
in	both	male	and	female	infantile	(PND	10)	rats.		
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Methods	
Housing	and	Diet	
Adult	Long-Evans	rats	(PND	80	–	100)	were	obtained	from	Harlan	(Indianapolis,	IN).	Care	
was	 taken	 to	 reduce	 BPA	 exposure	 in	 the	 housing	 environment	 by	 providing	 reverse	 osmosis	
water	 in	 glass	 or	 polysulfone	 drinking	 bottles	 and	 using	 polysulfone	 cages	 and	 beta-chip	
bedding.	 The	 Harlan	 2020X	 diet	 was	 chosen	 because	 it	 contains	 minimal	 amounts	 of	
phytoestrogens,	 which	 are	 well-known	 endocrine	 disruptors.	 During	 the	 2	 weeks	 prior	 to	
breeding,	 2	 to	 3	 females	 were	 housed	 per	 cage,	 and	 males	 were	 housed	 singly	 to	 prevent	
aggressive	behavior.	Handling	of	rats	was	performed	a	few	times	prior	to	the	start	of	the	study	
to	acclimate	rats	 to	 the	procedure,	and	 female	breeders	were	 trained	to	 receive	half	a	cookie	
(Newman’s	Own	Arrowroot	flavor,	Westport,	CT)	covered	with	tocopherol-stripped	corn	oil	(100	
µL)	 once	 returned	 to	 their	 cage.	 This	 particular	 cookie	 brand	was	 chosen	 because	 they	 have	
been	shown	to	contain	no	measurable	levels	of	BPA.	Breeding	was	initiated	by	cohabitating	one	
male	and	one	female	in	a	metal	cage	with	daily	monitoring.	Females	were	considered	pregnant	
upon	the	presence	of	a	sperm	plug.	Dams	were	then	housed	individually	for	the	gestation	and	
lactation	periods.	
	
BPA	exposure	
	 Our	 study	 involved	 exposure	 to	 BPA	 perinatally	 with	 both	 a	 prenatal	 and	 a	 postnatal	
exposure.	 Indeed,	 our	 original	 study	 was	 tailored	 towards	 BPA	 developmental	 neurotoxicity.	
Brain	development	in	the	rat	during	PND	0-9	mimics	development	during	the	third	trimester	of	
pregnancy	 in	 humans	 (Clancy,	 et	 al.,	 2007,	 Dobbing	 and	 Sands	 1979).	 The	 postnatal	 dosing	
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period	was	based	on	recent	evidence	that	lactation	results	in	very	low	BPA	exposure	in	rat	pups	
when	dams	are	dosed	orally	(Doerge,	et	al.,	2010).		
	 For	 the	 prenatal	 period,	 dosing	 of	 the	 dams	 started	 on	 gestational	 day	 (GD)	 3	 and	
stopped	upon	parturition	(GD	21	or	PND	0).	Treatment	groups	were	evenly	distributed	with	rats	
so	that	there	were	no	differences	in	overall	average	body	weight.	BPA	powder	was	suspended	in	
tocopherol-stripped	corn	oil	vehicle	to	make	0,	0.1,	and	1	mg	BPA/mL	oil	suspensions	that	were	
re-mixed	daily	with	a	stir	bar	to	ensure	homogeneity.	Vehicle	or	BPA	solution	(0.4	μL/g	of	body	
weight)	was	pipetted	onto	half	a	cookie	to	reach	the	following	doses:	0,	40,	and	400	ug	BPA	per	
kg	 of	 body	 weight.	 Cookies	 were	 allowed	 to	 dry	 before	 being	 given	 to	 the	 dams.	 All	 rats	
consumed	the	entire	half	cookie	within	5	minutes.	
	 To	start	the	postnatal	period,	litter	sizes	and	sex	ratios	were	recorded	on	PND	1.	On	PND	
2,	litters	were	culled	to	7-10	pups	per	dam	with	as	equal	a	sex	ratio	as	possible	between	litters.	
Stocks	of	0,	0.02,	and	0.2	mg	BPA/mL	oil	were	prepared	prior	to	each	cohort	and	re-mixed	daily.	
Dosing	 of	 the	 pups	 started	 on	 PND	 2	 and	 continued	 to	 PND	 10,	 at	 which	 point	 dosing	 was	
stopped	one	hour	prior	 to	sacrifice.	Each	pup	was	weighed	daily	and	two	separate	oral	doses,	
one	right	after	the	other,	for	a	total	of	2	µL/g	of	body	weight,	were	pipetted	into	their	mouth	to	
reach	the	same	dose	received	by	the	dams.	Both	oral	and	non-oral	dosing	of	neonatal-infantile	
pups	have	been	demonstrated	to	not	differ	in	active	levels	of	BPA	due	to	the	low	activity	of	liver	
enzymes	 (Taylor,	 et	 al.,	 2008).	 During	 dosing,	 pups	 were	 separated	 from	 the	 dam	 for	 10-15	
minutes.		
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Sample	collection	and	processing	
	 At	PND	10,	one	hour	 after	BPA	administration,	pups	were	euthanized	and	 trunk	blood	
was	collected	from	one	female	and	one	male	per	litter	in	glass	tubes	and	immediately	placed	in	
a	refrigerator	at	4°C.	Within	1	hour	of	collection,	blood	samples	were	spun	at	3500	rpm	for	10	
minutes	 and	 the	 plasma	 fraction	 was	 aliquoted	 and	 stored	 at	 -80°C	 until	 further	 processing.	
Samples	 from	 6	males	 and	 8	 females	were	 collected	 for	 the	 vehicle	 control	 group	 (BPA	 0),	 9	
males	and	9	females	for	the	40	µg/kg	BPA	group	(BPA	40),	and	10	males	and	9	females	for	the	
400	µg/kg	BPA	group	(BPA	400).		
	
FSH/LH	measurement	
FSH	and	LH	were	measured	using	a	multi-analyte	Luminex	kit	(Millipore,	St.	Charles,	MO,	
USA)	 according	 to	 the	manufacturer’s	 instructions.	 Briefly,	 plasma	 samples	were	 diluted	with	
serum	 matrix	 in	 a	 1:2	 dilution.	 Standards,	 quality	 controls,	 and	 samples	 were	 incubated	
overnight,	 after	 which	 antibodies	 and	 Streptavidin-Phycoerythrin	 were	 added.	 The	 plate	 was	
read	within	20	minutes	on	a	Luminex	plate	reader	(BioPlex	200	with	Bio-Plex	Manager	Software	
4.0;	BioRad,	Hercules,	CA,	USA).		
	
Steroid	extraction	
Steroid	 extraction	was	 carried	out	 to	 reduce	background	 interference	 in	 the	 ELISA	 kits	
(Tate	 and	Ward	 2004).	 Extraction	 was	 performed	 by	 adding	 ethyl	 acetate	 to	 plasma	 in	 glass	
culture	vials	(5:1	ratio)	and	thoroughly	mixing	by	vortexing.	Solutions	were	then	centrifuged	at	
3000	rpm	for	10	minutes	at	room	temperature	and	frozen	at	-20°C	overnight.	The	upper	liquid	
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organic	 phases	 were	 then	 transferred	 into	 new	 glass	 vials	 for	 evaporation	 using	 a	 rotary	
evaporator	at	40°C	 for	3	minutes.	Dried	 samples	were	 resuspended	 in	 steroid-free	 serum	 (IBL	
America,	Minneapolis,	MN,	USA),	vortexed	thoroughly,	and	stored	at	-20°C	until	ELISA	testing.	
	
Steroid	sex	hormone	ELISA	
Testosterone,	 progesterone,	 and	 estradiol	 were	 measured	 in	 extracted	 samples	 using	
commercial	 ELISA	 kits	 (IBL	 America,	 Minneapolis,	 MN,	 USA)	 according	 to	 the	 manufacturer’s	
instructions.	Samples	were	undiluted	with	the	exception	of	twelve	that	were	diluted	in	steroid-
free	serum	after	giving	saturated	signals	during	the	original	estradiol	analysis.		
	
Statistical	analysis	
Statistical	analyses	were	carried	out	using	SAS	9.3	(SAS	Institute	Inc.,	Cary,	NC).	
Preliminary	analyses	 for	each	hormone	 included	 summary	 statistics,	 probability	plots,	 and	 the	
Shapiro-Wilk	test	and	Anderson-Darling	test	to	determine	if	the	distribution	of	the	data	for	the	
hormone	 was	 Normal	 (Gaussian).	 Skewness	 and	 kurtosis	 (Mardia	 1970),	 and	 a	 test	 of	
multinormality	(Henze	and	Zirkler	1990),	were	used	to	determine	multivariate	normality	of	the	
five	hormones.	 The	M	 test	 (Box	1949)	was	used	 to	determine	homogeneity	of	 the	 covariance	
matrices	 for	 males	 versus	 females.	 Spearman	 rank	 correlations	 between	 all	 hormones	 were	
determined	for	female	pups,	male	pups,	and	all	pups.	Hormone	concentrations	of	each	variable,	
LH,	 FSH,	 testosterone,	 progesterone,	 and	 estradiol,	were	 standardized	 to	 a	mean	of	 zero	 and	
standard	deviation	of	1	so	that	all	categories	could	be	compared	on	the	same	unit-less	scale.	
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The	same	sample	from	each	pup	(one	of	each	sex	from	each	dam)	was	analyzed	for	all	
hormones	(LH,	FSH,	T,	P4,	E2)	on	the	pup	(within-subject	design).	Hormone	concentrations	were	
normalized	 using	 the	 log	 modulus	 transformation	 (John	 and	 Draper	 1980).	 The	 log	 modulus	
transformation	 of	 a	 value,	 y,	 is:	 sign(y)	 ×	 log10(y	 +	 1).	 Transformed	 values	 were	 analyzed	 as	
mixed-effects	 ANOVA	 (Proc	 GLIMMIX),	 where	 dam	 was	 a	 random	 factor	 and	 hormone,	
treatment,	and	sex	were	fixed	factors.		All	statistical	values	are	reported	and	discussed	in	terms	
of	the	transformed	values	and	adjusted	P-values	unless	specifically	stated	otherwise.		
The	male:female	ratio	is	reported	in	arithmetic	units,	and	was	estimated	using	an	online	
calculator	 from	GraphPad	 (2016)	 from	 the	 reported	mean	 and	 standard	 error	 of	 studies	 that	
measured	 sex	 hormones	 in	 PND	 9-11	 rats.	 Ratios	were	 evaluated	 rather	 than	 point	 hormone	
values	due	to	large	differences	in	the	scales	of	the	mean	concentrations	between	studies,	most	
likely	 due	 to	 differences	 in	 the	 cross-reactivity	 and	 sensitivity	 of	 the	 specific	 antibodies,	 and	
other	differences	in	detection	methods.	
P-values	for	selected	pairwise	comparisons	“hormone	x	sex”	and	“hormone	x	treatment	x	
sex”	 were	 Bonferroni-adjusted	 to	 maintain	 a	 family-wise	 Type	 I	 error	 rate	 of	 α	 =	 0.05.	 The	
selected	 comparisons	 were	 between-treatments	 within	 hormone	 and	 sex,	 or	 between	 sexes	
within	hormone	and	 treatment.	Other	pairwise	 comparisons	were	not	 selected,	e.g.,	between	
hormones	and	concurrently	between	sexes	and	treatments.		
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Results	
	 Summary	statistics	for	all	hormones	are	in	Table	15.	
		
Sex	differences		
Hormone,	 sex,	 and	 their	 interaction	 (hormone	×	 sex),	were	 statistically	 significant	 (p	 <	
0.05)	 (Table	 16).	 The	 treatment	 x	 sex	 and	 hormone	 x	 treatment	 x	 sex	 interactions	 were	 not	
statistically	 significant.	 These	 interactions	 are	 averaged	 over	 all	 hormones,	 which	 does	 not	
preclude	statistical	significance	for	some	combinations	discussed	below.		
Mean	hormone	concentrations	averaged	across	treatments	for	each	sex	were	statistically	
significant	 for	 the	 gonadotropins,	 FSH	 and	 LH	 (p	 <	 0.01),	 but	 not	 for	 the	 steroid	 hormones,	
estradiol	(E2),	progesterone	(P4),	or	testosterone	(T)	(p	>	0.5)	(Table	17,	Figure	1,	2).	Within	LH,	
all	treatment	groups	showed	statistically	significant	differences	between	males	and	females	(p	<	
0.01)	 (Table	 18,	 Figure	 1).	 For	 FSH,	 the	 BPA	 40	 and	 BPA	 400	 groups	 showed	 statistically	
significant	differences	between	males	and	females	(p	<	0.01)	(Table	18,	Figure	1),	but	the	control	
group	(BPA	0)	was	not	significant	(p	=	0.017,	α	=	0.01).	
	
Treatment	effect	
Treatment,	 and	 the	 treatment	 x	 sex	 x	 hormone	 interaction,	 and	 hormone	 x	 sex	
interactions,	were	not	statistically	significant	(all	p	>	0.3)	(Table	16).	Because	of	this,	treatment	
was	assumed	to	have	no	statistically	significant	influence	on	hormone	concentrations	and,	thus,	
further	analyses	of	pairwise	comparisons	for	treatment	(in	Appendices	3-5)	were	not	of	interest.	
For	hormone	x	treatment	x	sex	comparisons,	all	p	>	0.4	(Table	24).	
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Discussion	
Sex	differences	
Females	 showed	 higher	 baseline	 (untreated)	 FSH	 and	 LH	 concentrations	 than	 males	
(Table	17,	4,	Figure	1).	This	was	not	the	case	for	estradiol,	testosterone,	or	progesterone	(Table	
17,	 Figure	 2).	 Sex	 differences	 for	 FSH	 and	 LH	 are	 consistent	 with	 previous	 rat	 studies	 that	
reported	hormone	 levels	 in	both	sexes.	This	 study,	as	 in	previous	studies,	 found	 that	 levels	of	
FSH	in	males	were	lower	than	females	(males	were	39%	of	females,	compared	to	the	28%	which	
we	found)	(Table	18,	5).	The	sex	ratio	for	FSH	that	we	found	was	consistent	with	the	literature,	
with	the	previous	studies’	combined	confidence	interval	overlapping	our	confidence	interval	by	
100%.	Male	LH	levels	measured	in	previous	studies	were	51%	of	female	values,	compared	to	the	
53%	that	we	found	(Table	19).	Thus,	 the	particular	M:F	ratio	computed	for	FSH	and	LH	of	 this	
study	are	consistent	with	the	M:F	ratios	found	by	previous	studies.		
In	 contrast	 to	 the	 gonadotropins,	 steroid	 sex	 hormones	 were	 not	 different	 between	
males	and	females	for	estradiol,	progesterone,	or	testosterone	(Table	17).	The	sex	ratios	that	we	
found	 for	 the	 three	hormones	were	consistent	with	 the	previous	 literature,	with	our	estradiol	
results	overlapped	by	63%	of	the	previous	studies’	combined	confidence	interval,	progesterone	
overlapped	 by	 100%,	 and	 testosterone	 overlapped	 by	 66%	 (Table	 19).	 The	 lack	 of	 a	 sex	
difference	 in	 steroidal	 sex	 hormones	 for	 infantile/preweaning	 rats	 is	 also	 consistent	with	 the	
findings	of	the	first	chapter	of	this	thesis	(see	discussion	of	sex	differences	in	Chapter	1).	
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Treatment	effect	
Other	 than	 two	 studies	 of	 note,	 Kato,	 et	 al.,	 2006	 and	 Ramos,	 et	 al.,	 2003,	 there	 are	
limited	 published	 data	 on	 the	 effects	 of	 “relevant-dose,”	 perinatal	 BPA	 exposure	 on	 the	 sex	
hormone	profiles	of	 infantile	rats.	Here,	we	define	relevant-dose	exposure	as	below	500	μg/kg	
body	 weight	 oral	 BPA,	 based	 on	 studies	 in	 mice	 and	 rhesus	 monkeys	 that	 showed	 that	 oral	
exposure	 to	 400	 μg/kg	 body	 weight	 BPA	 leads	 to	 systemic	 blood	 levels	 comparable	 to	
epidemiologic	studies	that	measured	human	blood	and	urine	levels	of	BPA	(Taylor,	et	al.,	2011).	
In	the	Kato	study,	male	rats	were	postnatally	exposed	to	relevant-dose	BPA	and	hormone	levels	
were	determined	at	PND	10.	No	statistical	difference	was	found	on	body	weight,	mRNA	levels	of	
steroidogenic	enzymes,	mRNA	 levels	of	 steroid	hormone	receptors	 in	 the	 testes,	or	peripheral	
levels	 of	 testosterone.	 This	 is	 in	 contrast	 to	 the	 Ramos	 study,	 where	 relevant-dose	 BPA	 was	
limited	to	gestational	exposure.	Peripheral	testosterone	was	found	to	be	statistically	significantly	
increased	in	PND	15	male	rats.	The	conflicting	outcomes	of	the	two	studies	could	have	resulted	
from	a	number	of	reasons	related	to	different	laboratory	practices,	exposure	timing,	rat	strain,	
assay	methodology,	and	the	5-day	age	difference.		
Relevant-dose,	 perinatally	 administered	 BPA	 alters	 gonadotropin	 levels	 in	weaned	 and	
adult	males	(Bai,	et	al.,	2011,	Gamez,	et	al.,	2014,	Sadowski,	et	al.,	2014),	as	well	as	steroid	sex	
hormones	 (Chen,	 et	 al.,	 2014,	 Bai,	 et	 al.,	 2011,	 Aloisi,	 et	 al.,	 2002).	 Gonadotropins	 in	 female	
weanling	or	adult	rats	were	also	affected	by	relevant-dose,	perinatal	BPA	(Gamez,	et	al.,	2015,	
Sadowski,	 et	 al.,	 2014),	 as	were	 the	 steroid	 sex	 hormones	 (Gamez,	 et	 al.,	 2015,	 Aloisi,	 et	 al.,	
2002,	Durando,	et	al.,	2011).	However,	studies	have	also	reported	no	effects	in	both	genders	of	
rats	 of	 post-juvenile	 age	 that	 had	 been	 exposed	 perinatally	 exposed	 to	 relevant-dose	 BPA	
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(Akingbemi,	 et	 al.,	 2004,	Howdeshell,	 et	 al.,	 2007,	Ramos,	 et	 al.,	 2003,	 Ferguson,	 et	 al.,	 2011,	
2014,	Sadowski,	et	al.,	2014,	Gamez,	et	al.,	2014,	2015,	Nanjappa,	et	al.,	2012,	Kobayashi,	et	al.,	
2012,	 Aloisi,	 et	 al.,	 2002,	 Chen,	 et	 al.,	 2014,	 Durando,	 et	 al.,	 2011,	 Monje,	 et	 al.,	 2007).	 In	
summary,	there	are	conflicting	reports	of	the	effects	of	exposure	to	BPA	in	the	infantile	period,	
as	well	as	in	later	stages,	which	makes	it	difficult	to	reach	a	consensus	about	reproducibility	of	
relevant	dose	exposure	at	pre-adult	life	stages	in	the	rat	when	the	subject	has	been	brought	to	
discussion	(Melnick,	et	al.,	2002).	
In	the	present	study,	perinatal	BPA	treatment	of	40	or	400	μg/kg	bw	did	not	significantly	
affect	any	of	the	hormone	levels	tested	in	either	males	or	females.	These	results	are	consistent	
with	Kato,	et	al.,	(2006)	and	the	gonadotropin	results	of	the	Ramos,	et	al.,	(2003).	The	absence	
of	an	effect	on	infantile	rat	hormone	concentrations	does	not	predict	the	absence	of	observable	
effects	in	these	animals	as	the	immature	hypothalamic-pituitary-gonadal	system	associated	with	
sexual	 activity	matures.	Although	 the	hypothalamic-pituitary	unit	 is	 substantially	developed	at	
PND	10,	 it	 is	not	until	the	second	or	third	week	of	 life,	 in	the	middle-to-late	 infantile	period	in	
the	 female	 rat,	 that	 the	gonadal	unit—the	gonadotropin-responsive	 secondary	 follicles—begin	
to	form	and	begin	ovarian-mediated	secretion	of	estradiol	 (Prevot	2015).	Thus,	the	absence	of	
significant	 differences	 in	 female	 steroid	 hormone	 levels	 in	 fetal-neonatal	 rats	 exposed	 to	BPA	
relative	 to	 unexposed	 pups	 could	 be	 due	 to	 the	 underdevelopment	 of	 the	 ovaries	 at	 this	
exposure	period.	This	hypothetic	explanation	is	further	supported	by	the	absence	of	significant	
sexually	dimorphic	sex	steroid	profiles	 in	the	control	pups	of	this	study,	which	would	normally	
emerge	in	adulthood	(see	Chapter	1).	The	absence	of	effects	on	male	steroid	levels	can	possibly	
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be	 attributed	 possibly	 to	 the	 low,	 still	 growing,	 population	 of	 postnatal	 Leydig	 cells	 (Prevot	
2015).	
	
Study	Limitations	
The	 pulsatile	 nature	 of	 the	 secretion	 of	 hormones	 could	 potentially	 result	 in	 a	 wide	
variability	 in	 hormone	 levels	 and	 affect	 the	 statistical	 power	 of	 our	 study,	 especially	 in	
combination	 with	 the	 low	 number	 of	 animals	 that	 were	 used	 for	 each	 treatment	 group.	 In	
infantile	 rats,	 serial	 blood	 draws	 from	 the	 same	 subject	 are	 impractical	 given	 the	 volume	 of	
sample	needed	for	the	assays	(for	assays	 in	duplicate:	20	μl	 for	combined	FSH/LH	panel,	50	μl	
each	for	T	and	P4	ELISAs,	and	200	μl	for	E2	ELISA)	relative	to	the	size	and	total	blood	volume	(<	1	
ml)	of	each	animal.	Compensation	by	 including	a	number	of	 individual	 subjects	 from	different	
dams	or	the	same	dam	in	a	pooled	sample,	(along	with	appropriate	statistical	analysis	to	account	
for	subject),	are	the	common	alternatives	to	serial	draws.	
Calabrese	and	Baldwin	(2001)	stressed	the	importance	of	using	a	wide	range	of	dosages	
in	 order	 to	 detect	 non-monotonic	 dose-response	 curves.	 Although	 our	 study	 covered	 a	 wide	
range	 within	 the	 scope	 of	 dosages	 relevant	 to	 average	 human	 exposure,	 additional	 (more	
closely-spaced)	 doses	 within	 that	 interval	 would	 facilitate	 defining	 the	 shape	 of	 the	 dose-
response	curve.	
	
Conclusions	
Based	on	a	review	of	the	very	few	relevant	BPA	studies,	our	results	are	consistent	with	
some	 of	 what	 has	 been	 reported	 after	 relevant-dose	 BPA	 exposure	 in	 the	 infantile,	 juvenile,	
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peripubertal,	 and	 adult	 periods	 in	 rats.	 However,	 the	 literature	 is	 limited	 and	 sometimes	
contradictory	for	relevant-dose	perinatal	exposure	in	rats.	Although	relevant-dose	perinatal	BPA	
exposure	 in	 rats	may	 not	 affect	 sex	 hormone	 levels	 in	 infantile	 rats	 (from	what	we	 observed	
here),	 we	 cannot	 say	 that	 BPA	 does	 not	 affect	 infantile	 physiology	 in	 other	 ways,	 possibly	
through	 epigenetic	 mechanisms,	 that	 lead	 to	 immediate	 or	 delayed	 effects	 on	 other	
reproductive	(and	non-reproductive)	parameters	as	the	rats	mature.	Further	exploration	of	the	
effects	of	both	relevant	and	higher	dosages	of	BPA	on	a	wider	range	of	reproductive	parameters	
within	this	critical	developmental	time	in	the	 infantile	period	of	the	rat,	combined	with	similar	
observations	at	the	later	stages	of	development,	would	provide	vital	insight.	
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Tables	and	Figures	
Table	15.	Summary	statistics	by	hormone	and	sex	
	
	 	 	 Male	 	 Female	
	 Statistic	
	 BPA	0	 BPA	40	 BPA	400	 	 BPA	0	 BPA	40	 BPA	400	
(n	=	6)	 (n	=	9)	 (n	=	10)	 	 (n	=	8)	 (n	=	9)	 (n	=	9)	
FSH	
(pg/ml)	
Mean	 	 5568.6	 6590.5	 6684.7	 	 19611.1	 23903.4	 23958.7	
Median	 	 4269.4	 6271.7	 6721.2	 	 18401.2	 19139.7	 21558.5	
Min	 	 2809.2	 2214.6	 3750.5	 	 14634.1	 14785.0	 12837.2	
Max	 	 12299.3	 13377.3	 9789.8	 	 26336.5	 49713.6	 36748.4	
Std	Dev	 	 3518.7	 3334.4	 1928.4	 	 4449.3	 11465.2	 9312.6	
Std	Error	 	 1436.5	 1111.5	 609.8	 	 1573.1	 3821.7	 3104.2	
LH	
(pg/ml)	
Mean	 	 453.6	 406.3	 405.9	 	 855.6	 1072.6	 1039.7	
Median	 	 155.6	 97.0	 132.1	 	 565.6	 618.3	 1156.0	
Min	 	 -46.8	 -28.6	 7.6	 	 310.2	 253.6	 207.8	
Max	 	 2258.1	 1657.9	 1378.7	 	 2073.0	 2376.4	 1981.1	
Std	Dev	 	 888.4	 576.5	 475.2	 	 654.2	 814.8	 620.5	
Std	Error	 	 362.7	 192.2	 150.3	 	 231.3	 271.6	 206.8	
E2	
(pg/ml)	
Mean	 	 239.5	 248.4	 300.3	 	 765.7	 394.5	 445.7	
Median	 	 188.8	 208.8	 199.5	 	 311.5	 228.2	 194.6	
Min	 	 48.5	 182.4	 133.2	 	 52.0	 160.0	 131.2	
Max	 	 631.6	 596.6	 606.1	 	 2101.7	 1243.5	 2347.9	
Std	Dev	 	 201.0	 131.1	 194.9	 	 817.8	 364.0	 716.2	
Std	Error	 	 82.1	 43.7	 61.6	 	 289.1	 121.3	 238.7	
P4	
(ng/ml)	
Mean	 	 0.32	 0.27	 0.43	 	 0.36	 0.31	 0.30	
Median	 	 0.20	 0.20	 0.30	 	 0.30	 0.21	 0.27	
Min	 	 0.06	 0.04	 0.10	 	 0.04	 0.02	 0.03	
Max	 	 1.08	 0.77	 1.08	 	 0.88	 0.98	 0.67	
Std	Dev	 	 0.38	 0.23	 0.33	 	 0.27	 0.30	 0.20	
Std	Error	 	 0.16	 0.08	 0.10	 	 0.10	 0.10	 0.07	
T	
(ng/ml)	
Mean	 	 0.50	 0.34	 0.52	 	 0.23	 0.21	 0.21	
Median	 	 0.51	 0.27	 0.39	 	 0.19	 0.17	 0.19	
Min	 	 0.06	 0.04	 0.21	 	 0.04	 0.02	 0.03	
Max	 	 0.98	 0.88	 1.08	 	 0.91	 0.50	 0.51	
Std	Dev	 	 0.35	 0.25	 0.33	 	 0.28	 0.16	 0.13	
Std	Error	 	 0.14	 0.08	 0.10	 	 0.10	 0.05	 0.04	
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Table	 16.	 Main	 effects	 and	 interactions	 of	 sex	 and	 hormone	 on	 mean	 estimated	 hormone	
concentration.	
	
Type	III	Tests	of	Fixed	Effects	
Effect	 Num	DF	 Den	DF	 F	Value	 Pr	>	F	
Hormone	 4	 100	 737	 *<0.01	
Sex	 1	 20	 27	 *<0.01	
Hormone*Sex	 4	 80	 15	 *<0.01	
Treatment	 2	 25	 1	 0.35	
Treatment*Sex	 2	 20	 0.48	 0.63	
Hormone*Treatment	 8	 100	 0.44	 0.90	
Hormone*Treatment*Sex	 8	 80	 0.31	 0.96	
*statistically	significant	according	to	critical	value,	α	=	0.05	
	
Table	17.	Effects	of	sex	on	mean	estimated	hormone	concentration	by	hormone	(FSH,	LH,	E2,	P4,	
T)	averaged	over	all	treatments	
	
Differences	of	Least	Squares	Means	(Hormone	x	Sex)	
Hormone	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	 	
FSH	 0.36	 0.078	 80	 4.6	 *<0.01	 F	>	M	
LH	 0.62	 0.078	 80	 8.0	 *<0.01	 F	>	M	
E2	 0.017	 0.078	 80	 0.21	 0.83	 	
P4	 -0.045	 0.078	 80	 -0.58	 0.56	 	
T	 -0.047	 0.078	 80	 -0.61	 0.55	 	
*statistically	significant	according	to	Bonferroni-adjusted	critical	value,	α	=	0.05	/	5	=	0.01	
	
Table	18.	Effects	of	sex	on	mean	estimated	hormone	concentration	by	hormone	(FSH,	LH)	and	
treatment	(BPA	0,	BPA	40,	BPA	400)			
	
Differences	of	Least	Squares	Means	(Hormone	x	Treatment	x	Sex)	
Hormone	 Treatment	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	 	
FSH	 BPA	0	 0.38	 0.15	 80	 2.4	 0.017	 	
	 BPA	40	 0.36	 0.13	 80	 2.9	 *<0.01	 F	>	M	
	 BPA	400	 0.34	 0.12	 80	 2.8	 *<0.01	 F	>	M	
LH	 BPA	0	 0.77	 0.15	 80	 5.0	 *<0.01	 F	>	M	
	 BPA	40	 0.67	 0.13	 80	 5.2	 *<0.01	 F	>	M	
	 BPA	400	 0.43	 0.12	 80	 3.6	 *<0.01	 F	>	M	
*statistically	significant	according	to	Bonferroni-adjusted	critical	value,	α	=	0.05	/	6	=	0.0083	≈	0.01	
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Figure	1.	Gonadotropins	
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*Significant	sex	effect	(sex	x	hormone	interaction);	Bonferroni-adjusted	critical	value,	α	=	0.05	/	5	=	0.01	
**Significant	sex	effect	(sex	x	hormone	x	treatment	interaction);	Bonferroni-adjusted	critical	value,	α	=	0.05	/	6	=	0.0083	≈	0.01	
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Figure	2.	Steroid	hormones	
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Table	19.	Hormones	sex	ratios	around	PND	10-11	in	the	literature	
	
	 Source	 Kit,	antibody	 Strain	 n	 Male	 Female	 M:F	ratio	 90%	CI	
%	overlap	with	
previous	studies	
FSH	
(ng/ml)	
Döhler	&	Wuttke	1974	 RIA,	NIAMD	 SD	 3-8	 175	±	60	 892	±	244	 0.2	 0.07-0.45	 	
Döhler	&	Wuttke	1975	 RIA,	NIAMD	 SD	 8-15	 281	±	13	 752	±	111	 0.37	 0.29-0.51	 	
Dahl,	et	al.,	1988	 RIA,	NIDDKD	 SD	 3-4	 8.6	±	2	 21	±	3.9	 0.41	 0.21-0.73	 	
Kamberi,	et	al.,	1980	 RIA	 W	 5	 376	±	27	 880	±	32	 0.43	 0.37-0.49	 	
Ojeda	&	Ramírez	1972	 RIA,	NIAMD	 W	 6-8	 454	±	106	 860	±	118	 0.53	 0.30-0.83	 	
	 	 	 	 	 Avg:	 0.39	 0.07-0.83	 	
Current	study	 EIA	 LE	 6-8	 5.57	±	1.44	 19.61	±	1.57	 0.28	 0.15-0.43	 100%	
LH	
(ng/ml)	
Döhler	&	Wuttke	1974	 RIA,	NIAMD	 SD	 3-8	 30	±	7	 550	±	155	 0.05	 0.03-0.12	 	
Döhler	&	Wuttke	1975	 RIA,	NIAMD	 SD	 8-15	 34	±	6	 89	±	39	 0.38	 0.20-1.57	 	
Kamberi,	et	al.,	1980	 RIA	 W	 5	 110	±	8	 265	±	80	 0.42	 0.26-0.95	 	
Ojeda	&	Ramírez	1972	 RIA,	NIAMD	 W	 6-8	 417	±	43	 343	±	88	 1.22	 0.79-2.28	 	
	 	 	 	 	 Avg:	 0.52	 0.03-2.28	 	
Current	study	 EIA	 LE	 6-8	 0.46	±	0.36	 0.86	±	0.23	 0.54	 -0.22-1.60	 86%	
E2	
(pg/ml)	
Döhler	&	Wuttke	1975	 RIA,	NIAMD	 SD	 8-15	 142	±	10	 222	±	51	 0.64	 0.45-1.07	 	
Kamberi,	et	al.,	1980	 RIA	 W	 4	 165	±	21	 200	±	35	 0.83	 0.55-1.32	 	
Konkle	&	McCarthy	2011	 RIA,	DSL	 SD	 6	 17	±	0.038	 19	±	0.0014	 0.89	 0.89-0.90	 	
	 	 	 	 	 Avg:	 0.79	 0.45-1.32	 	
Current	study	 EIA	 LE	 6-8	 239.5	±	82.1	 765.7	±	289.1	 0.31	 0.11-1.04	 63%	
P4	
(ng/ml)	
Kamberi,	et	al.,	1980	 RIA	 W	 4	 3.2	±	0.3	 2.2	±	0.83	 1.46	 0.83-5.47	 	
Döhler	&	Wuttke	1974	 RIA,	NIAMD	 SD	 6	 0.88	±	0.071	 1.1	±	0.26	 0.80	 0.54-1.42	 	
Döhler	&	Wuttke	1975	 RIA,	NIAMD	 SD	 8-15	 2.8	±	5.5	 2.9	±	0.48	 0.97	 -2.36-4.46	 	
	 	 	 	 	 Avg:	 1.073	 -2.36-5.47	 	
Current	study	 EIA	 LE	 6-8	 0.32	±	0.16	 0.36	±	0.10	 0.89	 0.10-2.26	 100%	
T	
(ng/ml)	
Döhler	&	Wuttke	1975	 RIA,	NIAMD	 SD	 8-15	 0.64	±	0.22	 0.51	±	0.24	 1.26	 0.43-6.92	 	
Forest	1979	 RIA	 SD	 6-8	 0.19	±	0.012	 0.089	±	0	 2.13	 N.E.	 	
	 	 	 	 	 Avg:	 1.69	 N.E.	 	
Current	study	 EIA	 LE	 6-8	 0.50	±	0.14	 0.23	±	0.10	 2.17	 0.89-9.99	 66%	
	 	 	 	 	 	 	 	 	 	
Male	 and	 female	 values	 represent	means	 ±	 SEM	 extracted	 from	 original	 papers.	 Ratios	 (M:F)	 were	 calculated	 from	means	 and	 SEMs	 using	 an	 online	 GraphPad	
program	 (http://www.graphpad.com/quickcalcs/errorProp1/).	 “Current	 study”	 =	 the	 control	 group	 (BPA	 0)	 of	 this	 study,	 “antibody”	 =	 organization	 that	 provided	
antibodies,	“RIA”	=	radioimmunoassay,	“EIA”	=	enzyme-linked	immunosorbent	assay	(ELISA),	“SD”	=	Sprague-Dawley,	“W”	=	Wistar,	“LE”	=	Long-Evans,	“n”	=	number	
of	pups,	“N.E.”	=	not	estimable	due	to	zero	in	denominator.	
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Overall	Thesis	Conclusion	
Strain	differences	 in	steroidal	sex	hormone	profiles	were	 found	between	three	popular	
outbred	 strains	 of	 rat,	 Sprague-Dawley,	 Long-Evans,	 and	 Wistar.	 The	 strain	 differences	 were	
dependent	on	the	sex	and	age	of	the	animal,	and	likely	extend	to	other	reproductive	endpoints	
in	a	complex	manner.	These	differences	between	strains	in	the	profiles	of	sex	steroid	hormones	
may	point	to	inherent	differences	in	the	mechanisms	of	homeostatic	maintenance	of	hormone	
levels,	 and/or	 susceptibility	 to	 endocrine	 disruptors,	 that	 could	 at	 least	 partially	 explain	 the	
issues	in	the	inability	to	cross	compare	the	effects	seen	in	one	strain	versus	another,	leading	to	
the	lack	of	reproducibility	and	consistency	of	relevant-dose	effects.	However,	additional	studies	
of	specific	genetic	products	and	loci	involved	in	these	differences	in	baseline	hormone	levels	and	
responsiveness	 to	 endocrine-disrupting	 chemicals	 need	 to	 be	 conducted.	 Nevertheless,	 strain	
choice	is	certainly	a	factor	amongst	other	experimental	conditions	that	needs	to	be	considered	
when	conducting	an	animal	study.	
The	 second	 aspect	 of	 this	 thesis	 examined	 the	 effects	 of	 developmental	 exposure	 to	
relevant-dose	perinatal	BPA	on	still-developing	Long-Evans	rats.	In	this	study,	we	found	that	BPA	
produced	significant	alterations	on	hormone	profiles	of	neither	gonadotropins	nor	sex	steroids.	
This	 finding	 was	 consistent	 with	 some	 studies	 with	 similar	 experimental	 design,	 but	 also	
inconsistent	with	 others.	 The	 study	 further	 supports	 the	 notion	 that	 strain	 choice	may	 play	 a	
part	 in	 results	 obtained	 in	 a	 toxicological	 study,	 as	 it	 neither	 negates	 nor	 agrees	 with	 the	
majority	of	prior	study	outcomes.	Other	factors	such	as	stage	of	development	are	also	likely	to	
affect	the	observed	results	of	a	study.	
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In	conclusion,	consideration	for	basic	scientific	concepts	in	endocrine,	reproductive,	and	
metabolic	physiology,	genetic	variation	within	or	between	species,	and	developmental	dynamics	
all	govern	the	outcome	of	experimental	studies	on	reproductive	or	endocrine	alteration.	Thus,	
researchers	must	assure	that	they	have	adequate	understanding	of	these	systems	before	making	
conclusive	 resolutions	 on	 controversial	 chemicals	 such	 as	 BPA.	 Synthesizing	 such	 discoveries	
from	even	the	most	basic	physiology	still	expands	the	present	scope	of	knowledge	and	provides	
vital	clues	in	the	ongoing	struggle	to	elucidate	the	mechanisms	of	reproductive	toxicology.	
	 	
		 74	
Appendix	
Table	20.	Effects	of	 sex	on	mean	estimated	hormone	concentration	by	 treatment	 (BPA	0,	BPA	
40,	BPA	400).	
	
Differences	of	LSMs	(Treatment	x	Sex)	
Treatment	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	
BPA	0	 0.21	 0.069	 20	 3.1	 0.0058	
BPA	40	 0.20	 0.057	 20	 3.4	 0.0027	
BPA	400	 0.14	 0.054	 20	 2.5	 0.022	
	
Table	 21.	 Effects	 of	 sex	 (male	 vs.	 female)	 on	 mean	 estimated	 hormone	 concentration	 by	
hormone	(E2,	P4,	T)	and	treatment	(BPA	0,	BPA	40,	BPA	400)	
	
Differences	of	LSMs	(Hormone	x	Treatment	x	Sex)	
Hormone	 Treatment	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	
E2	 BPA	0	 0.031	 0.15	 80	 0.20	 0.84	
	 BPA	40	 -0.00094	 0.13	 80	 -0.01	 0.99	
	 BPA	400	 0.019	 0.12	 80	 0.16	 0.87	
P4	 BPA	0	 -0.051	 0.15	 80	 -0.33	 0.74	
	 BPA	40	 -0.026	 0.13	 80	 -0.21	 0.84	
	 BPA	400	 -0.059	 0.12	 80	 -0.48	 0.63	
T	 BPA	0	 -0.056	 0.15	 80	 -0.36	 0.72	
	 BPA	40	 -0.025	 0.13	 80	 -0.20	 0.84	
	 BPA	400	 -0.061	 0.12	 80	 -0.50	 0.62	
	
Table	 22.	 Effects	 of	 treatment	 (BPA	 0,	 40,	 400;	 A	 vs.	 B)	 on	 mean	 estimated	 hormone	
concentration	by	sex	
	
Differences	of	LSMs	(Treatment	x	Sex)	
Sex	 Treatment	A	 Treatment	B	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	
Female	 BPA	0	 BPA	40	 0.028	 0.026	 20	 1.1	 0.30	
	 BPA	40	 BPA	400	 0.0015	 0.025	 20	 0.06	 0.95	
	 BPA	0	 BPA	400	 0.026	 0.026	 20	 1.0	 0.32	
Male	 BPA	0	 BPA	40	 0.045	 0.086	 20	 0.53	 0.60	
	 BPA	40	 BPA	400	 -0.059	 0.075	 20	 -0.79	 0.44	
	 BPA	0	 BPA	400	 0.10	 0.084	 20	 1.2	 0.23	
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Table	 23.	 Effects	 of	 treatment	 (BPA	 0,	 40,	 400;	 A	 vs.	 B)	 on	 mean	 estimated	 hormone	
concentration	by	hormone	
	
Differences	of	LSMs	(Hormone	x	Treatment)	
	Hormone	 Treatment	A	 Treatment	B	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	
FSH	 BPA	0	 BPA	40	 0.044	 0.10	 100	 0.44	 0.66	
	 BPA	40	 BPA	400	 -0.014	 0.088	 100	 -0.16	 0.87	
	 BPA	0	 BPA	400	 0.058	 0.098	 100	 0.59	 0.55	
LH	 BPA	0	 BPA	40	 0.099	 0.10	 100	 0.99	 0.33	
	 BPA	40	 BPA	400	 -0.11	 0.088	 100	 -1.29	 0.20	
	 BPA	0	 BPA	400	 0.21	 0.098	 100	 2.16	 0.033	
E2	 BPA	0	 BPA	40	 0.065	 0.10	 100	 0.65	 0.52	
	 BPA	40	 BPA	400	 0.018	 0.088	 100	 0.21	 0.83	
	 BPA	0	 BPA	400	 0.046	 0.098	 100	 0.47	 0.64	
P4	 BPA	0	 BPA	40	 -0.014	 0.10	 100	 -0.14	 0.89	
	 BPA	40	 BPA	400	 -0.017	 0.088	 100	 -0.19	 0.85	
	 BPA	0	 BPA	400	 0.0025	 0.098	 100	 0.03	 0.98	
T	 BPA	0	 BPA	40	 -0.011	 0.10	 100	 -0.11	 0.91	
	 BPA	40	 BPA	400	 -0.017	 0.088	 100	 -0.20	 0.84	
	 BPA	0	 BPA	400	 0.0065	 0.098	 100	 0.07	 0.95	
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Table	 24.	 Effects	 of	 treatment	 (BPA	 0,	 40,	 400;	 A	 vs.	 B)	 on	 mean	 estimated	 hormone	
concentration	by	sex	and	hormone	
	
	
	
 
Differences	of	LSMs	(Hormone	x	Treatment	x	Sex)	
Sex	 Hormone	 Treatment	A	 Treatment	B	 Estimate	 Standard	Error	 DF	 t	Value	 Pr	>	|t|	
Female	 FSH	 BPA	0	 BPA	40	 0.038	 0.058	 80	 0.66	 0.51	
	 	 BPA	40	 BPA	400	 -0.0031	 0.056	 80	 -0.05	 0.96	
	 	 BPA	0	 BPA	400	 0.041	 0.058	 80	 0.71	 0.48	
	 LH	 BPA	0	 BPA	40	 0.049	 0.058	 80	 0.85	 0.40	
	 	 BPA	40	 BPA	400	 0.0024	 0.056	 80	 0.04	 0.97	
	 	 BPA	0	 BPA	400	 0.047	 0.058	 80	 0.80	 0.42	
	 E2	 BPA	0	 BPA	40	 0.049	 0.058	 80	 0.84	 0.40	
	 	 BPA	40	 BPA	400	 0.0083	 0.056	 80	 0.15	 0.88	
	 	 BPA	0	 BPA	400	 0.040	 0.058	 80	 0.70	 0.49	
	 P4	 BPA	0	 BPA	40	 -0.0016	 0.058	 80	 -0.03	 0.98	
	 	 BPA	40	 BPA	400	 -0.00037	 0.056	 80	 -0.01	 0.99	
	 	 BPA	0	 BPA	400	 -0.0012	 0.058	 80	 -0.02	 0.98	
	 T	 BPA	0	 BPA	40	 0.0043	 0.058	 80	 0.07	 0.94	
	 	 BPA	40	 BPA	400	 0.00050	 0.056	 80	 0.01	 0.99	
	 	 BPA	0	 BPA	400	 0.0038	 0.058	 80	 0.06	 0.95	
Male	 FSH	 BPA	0	 BPA	40	 0.050	 0.19	 80	 0.26	 0.79	
	 	 BPA	40	 BPA	400	 -0.025	 0.17	 80	 -0.15	 0.88	
	 	 BPA	0	 BPA	400	 0.075	 0.19	 80	 0.40	 0.69	
	 LH	 BPA	0	 BPA	40	 0.15	 0.19	 80	 0.77	 0.44	
	 	 BPA	40	 BPA	400	 -0.23	 0.17	 80	 -1.37	 0.17	
	 	 BPA	0	 BPA	400	 0.38	 0.19	 80	 2.01	 0.048	
	 E2	 BPA	0	 BPA	40	 0.081	 0.19	 80	 0.42	 0.67	
	 	 BPA	40	 BPA	400	 0.029	 0.17	 80	 0.17	 0.86	
	 	 BPA	0	 BPA	400	 0.052	 0.19	 80	 0.28	 0.78	
	 P4	 BPA	0	 BPA	40	 -0.027	 0.19	 80	 -0.14	 0.89	
	 	 BPA	40	 BPA	400	 -0.033	 0.17	 80	 -0.20	 0.84	
	 	 BPA	0	 BPA	400	 0.0062	 0.19	 80	 0.03	 0.97	
	 T	 BPA	0	 BPA	40	 -0.026	 0.19	 80	 -0.14	 0.89	
	 	 BPA	40	 BPA	400	 -0.035	 0.17	 80	 -0.21	 0.83	
	 	 BPA	0	 BPA	400	 0.0092	 0.19	 80	 0.05	 0.96	
